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The first workers to use the isolated perfused rat liver for the study of gluconeogenesis 
were Corey and Britton (1941). Subsequently, other investigators found the modified 
method of Miller et al (1951) to be more suitable. This technique, with modifications intro-
duced by Mortimore (1961) and Hems et al (1966) was used in the present study. 
The isolated liver is perfused through the portal vein with saline, supplemented by bovine 
serum albumin and washed human erythrocytes, under a pressure of about 20cm of water, 
maintained by a reservoir of adjustable height. The perfusate which passes through the 
liver enters the inferior vena cava and passes, via a cannula, to a collecting vessel from 
which it is pumped to the top of a multiple bulb oxygenator and then returned to the liver 
for re-perfusion. This technique has proved to be a satisfactory means of assessing 
changes in the metabolic status of hepatic cells in response to starvation and exposure to 
halothane. 
The study described here was performed to determine whether the isolated liver perfusion 
technique can be used to measure the effects on liver perfusion of therapeutic and supra-
therapeutic doses of various drugs, some of which have been reported to affect liver me-
tabolism adversely in the intact animal. 
Liver function was assessed by studying gluconeogenesis and bromosulphthalein 
clearance. Alcohol and hexane were administered in toxic doses, rifampicin and isoniazid 
in high doses and paracetamol in therapeutic doses. 
Inbred male Wistar rats were used for these studies. Hexane was injected sub-
cutaneously, while the other drugs were given per os on 7 consecutive days each week for 
a period of 90 days; with the exception of the control group in the hexane study, all the 
control groups were untreated. 
Pyruvate, a precursor for gluconeogenesis (synthesis of glucose from non-carbohydrate 
sources) is an excellent substrate for the formation of oxaloacetate, which is probably an 
obligatory intermediate in the pathway to glucose synthesis. It has been used over a num-
ber of years by different investigators who have .studied gluconeogenesis using the iso-
lated liver perfusion technique. It was used for the same purpose in the present study. 
v 
Methylene blue, a redox dye, capable of oxidising NAOH to NAO +, was used to determine 
whether an altered NAOH : NAO + ratio would have any effect on the output of glucose in 
the ethanol, paracetamol and hexane studies. Fructose, a non-NAO+ dependent precur-
sor of glucose. was also used for this purpose in the ethanol study. 
All the drugs studied were found to inhibit gluconeogenesis. This was shown by a 
decrease in glucose levels and an increase in lactate : pyruvate ratios in the perfusion 
medium of experimental livers. The decreased glucose production by the experimental 
livers, which occurred pari passu with an increased pyruvate utilization, indicates that in 
these animals pyruvate was used for the production of other compounds such as lactate. 
In contrast. glucose production and pyruvate utilization were increased in the control 
group indicating that pyruvate was used mainly for the production of glucose. 
In the ethanol group, impaired gluconeogenesis was probably due to a change in the 
NAOH : NAO + ratio; when methylene blue was introduced into the perfusion medium of 
this group the output of glucose was high. 
Impaired gluconeogenesis in the paracetamol and hexane-treated groups was probably 
related to the non-availability of oxaloacetate or impairment of the activity of key enzymes 
involved in gluconeogenesis; when methylene blue was added to the perfusion medium of 
these animals the glucose output remained low. 
Except for the rifampicin study. bromosulphthalein clearance was impaired in all the ex-
perimental groups. Histological examination of liver tissue obtained from the hexane-
treated animals demonstrated severe fatty change. 
In conclusion, these studies have demonstrated that the isolated liver perfusion technique 
is a suitable method of evaluating the effect of therapeutic and supra-therapeutic doses of 
some drugs which affect hepatic function. 
Ethanol. isoniaZid. rifampicin. paracetamol (in therapeutic doses) and hexane were found 
to alter liver function as evidenced by impaired gluconeogenesis and bromosulphthalein 
clearance. In addition, histological evidence of liver damage was noted in rats treated with 
hexane. 
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The liver is the major site of gluconeogenesis with the kidney becoming an important site 
during starvation and acidosis (Exton and Park, 1967; Exton, 1972). Attempts to study 
gluconeogenesis in rat liver slices met with major difficulties. The rate of gluconeogenesis 
obtained with substrates such as succinate, malate, fumarate, glutamate and aspartate 
were unexpectedly low or even nil. Pyruvate and lactate formed glucose but less rapidly 
than expected (Hems, et al 1966). These observations show that liver slices have limited 
scope in the study of gluconeogenesis and it was largely as a result of this finding that the 
technique of the isolated perfused rat liver was developed. 
Initially, workers perfused livers of larger animals, mainly dogs, because the surgical and 
chemical analytical techniques available were on "macro" scale. The first to use the per-
fused rat liver were Corey and Britton (1941), Trowell (1942) and Miller, Bly, Watson and 
Bale (1951). The method of Miller et al (1951) proved to be the most acceptable to subse-
quent workers and this technique, with modifications introduced by Mortimore (1961) and 
Hems et al (1966), was the starting point of this investigation. Miller et al perfused the iso-
lated liver through the portal vein with heparinized rat blood under a pressure of about 20 
cm of water, maintained by a reservoir of adjustable height. Mortimore (1961) perfused 
the liver in situ, isolating the circulation from the donor animal. Schimassek (1963) re-
placed blood as perfusate with a saline medium containing bovine albumin and bovine 
erythrocytes. The perfusion medium used in this study was that of Hems et al (1966) 
which consisted of physiological saline (Krebs and Hensleit 1932), bovine serum albumin 
and washed human red cells. 
Many experiments were carrried out in which modifications of the perfusion medium were 
tested, using the flow of medium through the liver and the rate of glucose formation from 
lactate as criteria of efficacy. Omission of albumin from the medium caused gross swelling 
of the liver and exudation of fluid from the surface. Varying the concentration of albumin 
between 1.5% and 6% made no difference. De-ionized haemaccel, a plasma expander, 
used instead of albumin, gave a good perfusion flow but some haemolysis occurred and 
the rate of glucose formation from lactate was reduced. Replacement of albumin (2.6%) 
by dextran (40 or 80) led to clumping of red blood cells and a cessation of flow (Gronwall, 
1957). Omission of red cells made no difference, provided that the livers weighed at least 
5 g and that the flow was rapid, not less than 30 mljmin. 
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This technique, with various modifications, has been used over a number of years by dif-
ferent investigators in the study of gluconeogenesis (Hems et ai, 1966; Ross et ai, 1966), 
lactate production (Woods and Krebs, 1971) and glycogen, carbohydrate, fatty acid and 
xylitol metabolism (Sokal et ai, 1959; Ross et ai, 1967; Krebs and Hems, 1970; Woods and 
Krebs, 1973). It has also been used to Investigate the effects of alcohol on 
gluconeogenesis (Forsander et ai, 1965; Krebs et ai, 1969; Krebs et ai, 1969) and albumin 
synthesis (Kirsch et ai, 1973). In addition, this technique was used to test 
bromosulphthalein clearance after the administration of nafenopin (Gartner et ai, 1982), 
halothane (Biebuyck et ai, 1970), norbolethone (Bassan et ai, 1971) chlorpromazine 
(Kendler et ai, 1971) and albumin (Gumucio et ai, 1984). The technique is based upon the 
cannulation of the portal vein and the inferior vena cava just below the right atrium. The 
liver is isolated by a tie on the abdominal aorta. The liver is perfused through a cannula in 
the portal vein. After passing through the liver, the perfusate is collected by a cannula tied 
into the vena cava just below the right atrium. 
The technique was incorporated in the design of the present study for two reasons: 
i) The isolated rat liver provides the possibility of studying many aspects of liver me-
tabolism with much greater accuracy than is practical in the whole organism. 
Ii} The perfused organ has proved to be a better experimental model than liver slices 
and homogenates because much of the normal metabolic capacity as well as the 
control mechanisms are lost on disturbing the structure of the organ. 
The object of this thesis has been to examine whether the isolated liver perfusion tech-
nique can be used to measure the effects on liver function of therapeutic and supra-
therapeutic doses of drugs, some of which have been reported to affect liver metabolism 
adversely in the intact animal. 
The drugs used were alcohol, isoniazid, rifampicin, paracetamol and hexane. Alcohol was 
chosen because its toxic effects on the liver are well documented; metabolic events such 
as hypoglycaemia and histological abnormalities including fatty change, alcoholic hepatitis 
and cirrhosis can complicate alcoholism (MacSween, 1983). Isoniazid and rifampicin are 
first line drugs in the treatment of tuberculosis; jaundice may complicate therapy with 
either of these drugs (Davies and Glowinski, 1961; Maddrey, 1981; Capelle et ai, 1972; 
Kenwright and Levi, 1974). Paracetamol, a commonly used non-narcotic analgesic, is a 
major component of many formulations available for the relief of colds, fever, headache 
and cough (Ameer and Greenblatt, 1977). Liver damage with overdose has been well 
documented (Record et ai, 1981; Davis, 1986; Monteagudo and Folb, 1987). Chronic 
hepatic inflammation and fibrosis due to low doses of the drug have been reported 
2 
(Bonkowsky, 1978) but no literature regarding chronic dosing with therapeutic doses of 
this drug is available. Solvent abuse or glue-sniffing has become an increasing problem in 
the young and a wide variety of substances have been involved (Glaser et ai, 1962; Wat-
son, 1979). Benzine and glue, which contain hexane in high concentrations, are com-
monly inhaled by individuals intent upon producing a state of euphoria (Edward, 1982). 
The effects of hexane on the liver have not previously been studied, whereas its toxic ef-
fects on the nervous system are well known (Spencer et ai, 1980; Lalla et ai, 1981). Liver 
function was assessed by studying gluconeogenesis and bromosulphthalein clearance. 
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CHAPTER 2 
MATERIALS AND METHODS 
MATERIALS AND METHODS 
Experimental Animals 
85 Wistar rats were used during the investigation of the effects of toxic doses of alcohol 
and hexane, high doses of isoniazid and rifampicin, and therapeutic doses of paracetamol 
on hepatic function in vitro. 
All were inbred male rats obtained from the animal colony, University of Natal Medical 
School. 
Caging 
All the animals were kept in polypropylene boxes with metallic grills in the animal colony. 
The rats were housed three to a cage. 
Numbering of Rats 
The rats were individually earmarked for identification, by nicking the ears according to the 
diagram below. 
1 3 
right ear left ear 
4 
Higher numbers were indicated by more than one nick. 
4 
Bedding 
Wood shavings (pine and meranti wood) were placed in each box to a depth of about 4 
cm to serve as bedding. Bedding was changed on a weekly basis. 
Routine Diet 
Pelleted rat food was provided in food hoppers and water were given by bottle. Both food 
and water was supplied ad libitum and changed thrice weekly. The composition of the 
standard laboratory rat food is shown in Table 1. 
Environmental conditions 
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The drugs used in the study, their dosage and route of administration are shown in Table 2. 
TABLE 2 
DRUG DOSE/DAY DURATION ROUTE OF ADMINISTRATION 
Alcohol 25% soln 90 days per os 
Isoniazid 2.5mg 90 days per os 
Rifampicin 4.0mg 90 days per os 
Paracetamol 0.005g 90 days per os 
Hexane 0.2ml 90 days subcutaneously 
The doses used were toxic (alcohol and hexane), high (isoniazid and rifampicin) and therapeutic 
(paracetamol). 
Statistical Analysis of Results 
Statistical analyses of results were carried out using the Mann Whitney Rank Sum test with 





The medium used was that described by Hems, Ross, Berry and Krebs (1966). The perfu-
sion medium contained :-
a) physiological saline 
b) bovine serum albumin 
c) washed human red blood cells. 
The physiological saline was prepared to the method of Krebs and Hensleit (1932). Com-
position of the physiological saline is set out in appendix A. 
Purification of Bovine Serum Albumin 
5g of bovine serum albumin was dissolved in 100 ml of saline (Krebs and Hensleit, 1932) 
by stirring. This solution was dialysed against 250ml of saline for 48 hours, and then 
repeated. Since the bovine serum albumin was acidic, pH was adjusted to 7.4 by the ad-
dition of N NaOH. 
Preparation of Red Blood Cells 
Human red blood cells stored at 4°C and no longer suitable for transfusion were obtained 
from the blood bank at King Edward VIII Hospital. 100ml of the whole blood was 
centrifuged at 1500 rpm for 20 minutes. The buffy layer and plasma were removed by suc-
tion and red cells washed 4 times with physiological saline gassed with carbogen (95% 02 
: 5% CO2), The washing fluid was removed by centrifugation for 10 min at 1500rpm and 
washed cells made up to 100 ml with saline. 
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Preparation of Perfusion Medium 
The total volume of perfusion medium was 150 ml which consisted of 100 ml of purified 
bovine serum albumin ( 3.3% w Iv) and 50 ml of red blood cell suspension. 
Methods Employed for Biochemical Analysis 
pyruvate was measured by the U.V. method of Czok R and Lamprecht W (1974) which 
included sample deproteinization by hypochloric acid. 
Lactate by the U.V. method of Gutmann I and Wahlefeld A W (1974) which included 
sample deproteinization by 0.6 N hypochloric acid. 
Glucose by the Beckman enzymatic glucose reagent method (Hexokinase endpoint). 
Bromosulphthalein clearance spectrophotometrically by the method of Henry et al 
(1959) which included sample deproteinization by acetone. 
Operative Technique 
Rats were anaesthetised by intraperitoneal injection with a fresh solution of sodium pen-
tobarbital (60 mg/kg) and then 0.1 ml of heparin was administered via the saphenous vein. 
Cannulae were inserted as shown in (Fig. 1). The bile duct was first cannulated after which 
cannulation of the portal vein was achieved. Finally a cannula which consisted of a portex 
tubing cut to a sharp-point to facilitate piercing of the right atrium, was placed in the in-
ferior vena cava proximal to the liver. All cannulae were secured by ties, using silk 3/0. 
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Fig. 1 Diagram of the operative procedure for in situ perfusion of the rat liver. 
RIGHT 
The portal vein and bile duct are cannulated, the portal vein being tied dis-
tally. The cannula in the inferior vena cava is inserted through the wall of the 
right atrium and tied in place above the diaphragm. The inferior vena cava is tied 








Fig. 2 Diagram of the liver perfusion apparatus showing the direction of circulation of the 
medium. The medium in the collecting vessel Is pumped through the nylon mesh 
filter to the top of the oxygenator. The medium then passes to the reservoir and 
enters the portal vein; the excess medium returns to the collecting vessel. The 
venous outflow is directed into the syphon. 
BULB 
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BI4 JOINT TO FIT 













Fructose (500mg) a non-NAD + dependent precursor of glucose was added at the start of 
the perfusion which continued for 75 minutes. The capacity of the alcohol injured liver to 
synthesise glucose from fructose was measured by taking samples at 15 minute intervals 
for the measurement of glucose. 1ml 10% solution of methylene blue, a redox dye 
capable of oxidising NADH to NAD +, was added at start of perfusion which continued for 
75 minutes. 
Glucose synthesis, by the isolated liver, damaged by drug administration, was measured 
by taking five samples at 15 minute intervals for the measurement of glucose levels. 
Microscopy 
The liver tissue from the hexane study was fixed for 24 hours in 10% buffered formalin 
solution, embedded in paraffin wax and Sum thick sections cut. All the sections were 







While there are many alcohols in use, this study deals exclusively with ethanol. It is con-
sumed in a vast variety of forms ranging from ales (3-6% alcohol by weight) to distilled 
spirits such as gin and whisky (35% or more alcohol by weight). It is also used in the 
parenteral nutrition of patients who are unable to take food or liquid by mouth . 
. Physical and Chemical Properties 
Ethanol is a clear, colourless, mobile, volatile, readily inflammable liquid with a characteris-
tic spiritous odour and burning taste. Ethanol can be produced in nature by fermentation 
of carbohydrates or synthetically. It has a boiling point of about 7SoC with a specific 
gravity of 0.806. It is miscible with water, acetone, chloroform, ether, glycerol and almost 
al\ other organic solvents. The molecular formula of ethanol is C2H50H and the molecular 
weight is 46,07g. 
Structure of Ethanol 
H H 





Over half of alcohol absorption, after oral ingestion, occurs in the stomach where the process is 
rapid, but it is even more rapid in the small intestine. Absorption is complete when the alcohol 
content of the gastrointestinal tract reaches equilibrium with the remainder of the body water, both 
intracellularly and extracellularly. 
14 
Metabolism 
The toxic effects of ethanol on the liver are, in part, determined by the fact that it is preferentially 
metabolised in the hepatocytes, and only about 2-10% of the absorbed ethanol is eliminated via 
the lungs and kidneys; skeletal muscle cannot utilize ethanol. In the liver cell about 90% of the ab-
sorbed ethanol is metabolised in the cytosol by the action of alcohol dehydrogenase (ADH) and is 
converted to acetalydehyde with the release of (H+) ions. The major and minor pathways of 
ethanol metabolism are illustrated schematically in (Fig.3). 
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Fig. 3 Schematic representation of pathways of ethanol metabolism 
MAJOR PATHWAY 
ALCOHOL DEHYDROGENASE ALDEHYDE DEHYDROGENASE 
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Nicotinamide adenine dinucleotide (NAO+) acts as an H+ ion receptor and is converted to NAOH, 
consequently changing the NAOH : NAO + ratio and the redox state within the cell. This change in 





The accumulation of free NAOH with a resultant increase in NAOH : NAO + ratio; 
An increase in lactate : pyruvate ratio and development of hyperlactaemia (but usually the 
acidosis is not severe); 
Inhibition of the tricarboxylic acid cycle through the reduction reactions which require 
NAO+; 
Possible inhibition of hepatic gluconeogenesis which results in hypoglycaemia. 
The rate-limiting step in ethanol metabolism appears to be the availability of NAO + and this, in turn, 
will depend on the rate of re-oxidation of NAOH, a mitochondrial function. 
Experimental Design 
Since isolated liver perfusion is an established method of studying gluconeogenesis in vitro (Hems 
et ai, 1966), it appeared likely that this technique would be suitable for determining the effects of 
chronic administration of drugs on liver function. In order to confirm this hypothesis, the effect of a 
known hepatotoxin, ethanol, on gluconeogenesis and bromosulphth?lein clearance was studied 
using this method. Ethanol was chosen for investigation because it produces hypoglycaemia by 
inhibiting gluconeogenesis (Field et ai, 1963; Forsander et ai, 1965; Frienkel et ai, 1965; Kaden et 
ai, 1969; Krebs et ai, 1969; Lochner et ai, 1967; and Madison, 1969). 
Materials and Methods 
Four groups of 6 rats, each weighing 200-210g, were used in this study. Fluids to drink were given 
ad libitum; the control group were given tap water and the three experimental groups a solution of 
25% alcohol in water for a period of 90 days. The livers of control and of one experimental group 
of rats were perfused for 75 minutes with a medium containing pyruvate (500umoles), a 
glucon~ogenic precursor, and subsequently these livers were perfused with a medium containing 
bromosulphthalein (1.25 mg/100g rat weight) for an additional 20 minutes; those of the 2nd ex- . 
peri mental group of rats were perfused for 75 minutes with a medium containing pyruvate 
(500umoles) and a 1 ml 10% solution of methylene blue, a redox dye capable of oxidising NAOH to 
NAO+ , and those of the 3rd experimental group of rats with fructose (500mg), a non-NAO+ de-
pendent precursor of glucose, for 75 minutes. The animals were randomly chosen for perfusion. 
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Serial specimens were obtained at 15 minute intervals for the analysis of glucose, lactate and 
pyruvate and at 5 minute intervals for bromosulphthalein clearance from perfusate and biliary 
excretion of the dye. 
ResuHs 
After drinking ethanol for 12 weeks, the rats appeared healthy and not visibly different from control 
animals. The condition . of the livers remained good during two hours of perfusion at 37°C as 
judged by gross appearance and linear rates of glucose production. The time course of glucose 
and lactate production by the livers of control and experimental animals, pyruvate concentrations, 
lactate:pyruvate ratios and rates of glucose and lactate production are shown in Tables 3a and 3b . 
respectively and illustrated graphically (Figs. 4-7). 
Gluconeogenesis 
When the livers were perfused with a medium containing pyruvate (500umoles) for 75 minutes, 
measurable amounts of glucose and lactate were formed. Glucose formation was linear, the 
average glucose concentration derived from the perfusate after 75 minutes perfusion was 6.33 
mmoles/I, and formation at an average rate of 0.12 mmoles/min per g wet weight of liver in the 
control group, while in the experimental group the glucose concentration was 1.97 mmoles/I, and 
formation at an average rate of 0.02 mmoles/min per g wet weight of liver. 
Lactate formation was linear, the mean lactate concentration derived from the perfusate at the end 
of perfusion was 2.63 mmoles/I and formation at a mean rate of 0.02 mmoles/min per g wet weight 
of liver in the control group while in the ethanol-treated group the concentration was 3.10 mmoles/I 
and formation at a mean rate of 0.03 mmoles/min per g wet weight of liver. 
305 umoles of pyruvate was utilised in the control group such that the lactate:pyruvate ratio was at 
a value of about 13 whereas 385 umoles was used in the ethanol group such that the 
lactate:pyruvate ratio was at a value of about 26. The rate of glucose formation, glucose and 
pyruvate concentrations were decreased and lactate:pyruvate ratios increased in the experimental 
group compared to controls (p<0.05 for all comparisons). 
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Glucose Formation 
lml 10% methylene blue (a redox agent capable of oxidising NAOH to NAO+) was added to the 
perfusion medium containing pyruvate at the beginning of the perfusion. Methylene blue has been 
reported to reverse alcohol inhibition of gluconeogenesis. Methylene blue overcame the ethanol 
inhibition of pyruvate conversion to glucose and the glucose concentration was higher with 
methylene blue (11.33mmoles/l) than that of pyruvate alone (1.97 mmoles/I) . A significant in-
crease in glucose production was noted after the addition of methylene blue (p<0.05; Fig 8). 
Fructose (500mg), a non-NAO+ dependent precursor of glucose, was added at the start of the per-
fusion. Ethanol did not inhibit fructose utilization or its conversion to glucose. After 75 minutes of 
perfusion the glucose concentration derived from perfusate containing fructose was 7.43 mmoles/I 
. and 1.97 mmoles/I with pyruvate alone. Since fructose has no requirement for NAO +, inhibition 
would not be expected. A significant increase in glucose production was observed after the addi-
tion of fructose (p<0.05; Fig. 9) . 
Bromosulphthlein Clearance 
Bromosulphthalein was added, at a dosage of 1.25mg/l00g donor rat weight, to the perfusate 
reservoir 80 minutes after beginning the perfusion. The time course of bromosulphthalein 
clearance from perfusate and biliary excretion of the dye are shown in Table 3c. The 
bromosulphthalein percentage retention was 45.6% after 12 weeks of ethanol feeding compared to 
9.4% in control animals. The clearance of bromosulphthalein from perfusate (p<0.005; Fig. 10) 
and biliary excretion of dye (p<0.05 for all comparisons except 5 minute biliary excretion level; Fig. 
11) were impaired in the experimental animals. 
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Table 3a 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF CONTROL RATS (n=6) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±.. SEM. The initial volume of the medium was 150 ml; it decreased every 15 minutes by 10ml. (removed for analysis). 
The livers had a mean wet weight of 6.48g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmolesjl) 
LACTATE 2.09 .±..0.11 2.28 ,±,,0.13 2.44 .±..0.13 2.68 .±..0.11 2.63 .±..0.16 
PYRUVATE 0.190 .±..0.01 0.208 .±..0.04 0.202 .±..0.01 0.187 .±..0.01 0.190 .±..0.008 
GLUCOSE 3.05 .±..0.17 3.69 .±..0.22 4.73 .±..0.57 5.42 .±..0.49 6.33 .±..0.52 
LACTATE:PYRUVATE ratios ' 11.41 .±..1.1 10.98 .±..0.65 12.19 .±..0.79 14.72 .±..1.30 13.82 .±..0.85 
METABOLIC RATES (mmoles j min per g wet weight of liver) 
GLUCOSE FORMATION 0.09 0.16 0.11 0.14 
LACTATE FORMATION 0.03 0.02 0.04 -0.007 
2 0 
Table 3b 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF EXPERIMENTAL RATS (n=6) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150ml; it decreased every 15 minutes by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.23g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmolesjl) 
LACTATE 2.78 .±.0.24 3.13 .±.0.43 2.92 .±.0.26 2.97 .±.0.27 3.10 .±.0.29 
PYRUVATE 0.108 .±.0.004 0.112 .±.0.004 0.111 .±.0.004 0.107 .±.0.004 0.127 .±.0.001 
GLUCOSE 1.28 .±.0.04 1.5 ,±,0.13 1.75 .±.0.26 2.13 .±.0.20 1.97 .±.0.13 
LACTATE:PYRUVATE ratios 25.83 .±.2.4 27.45 .±.3.1 26.72 .±.3.1 27.77 .±.2.9 24.72 .±.1.1 
. METABOLIC RATES (mmoles j min per g wet weight of liver) 
GLUCOSE FORMATION 0.03 0.04 0.06 -0.02 
LACTATE FORMATION 0.06 -0.03 0.008 0.02 
.21 
Table 3c 
TIME-COURSE OF BROMOSULPHTHALEIN CLEARANCE BY PERFUSED LIVERS OF CONTROL AND EXPERIMENTAL RATS 

























































Fig.4 Glucose concentrations derived from perfusate of isolated perfused livers of con-
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Fig. 5 Lactate concentrations derived from perfusate of isolated perfused livers of control 













Fig. 6 Pyruvate concentrations derived from perfusate of isolated perfused livers of control and alcohol-treated rats 
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Fig. 7 Lactate:Pyruvate ratios derived from perfusate of isolated perfused livers of control 
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Fig. 8 The effect of methylene blue, a redox agent, on glucose concentrations derived from perfusate of isolated perfused livers of control 
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Fig. 9 The effect of fructose, a non-NAD + dependent precursor, on glucose concentrations derived from perfusate of Isolated 
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c =NS 
Fig. 11 Biliary excretion of bromosulphthalein derived from the bile of control and alcohol- treated rats 
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DISCUSSION 
When pyruvate, a substrate for gluconeogenesis, was added to the perfusion medium, 
pyruvate utilization and glucose production were increased in the controls, indicating that 
the added pyruvate was utilized for the production of glucose. In contrast, glucose 
production by the alcohol-treated livers decreased, indicating that gluconeogenesis was 
impaired. This finding is in agreement with that of other workers (Freinkel et ai, 1965; 
Kreisberg et ai, 1971; Wilson et ai, 1981). 
The addition of methylene blue to the perfusion medium containing pyruvate resulted in a 
significant increase in glucose production by the experimental animals. Since methlyene 
blue is a redox agent capable of oxidising NADH to NAD + , these findings support the view 
that an increased free NADH : free NAD + ratio generated during ethanol metabolism is the 
primary mechanism by which gluconeogenesis is inhibited (Lochner et ai, 1967; Madison 
1968). Other workers have reported that alcohol suppressed glucose production in fasting 
dogs with portocaval shunts, and that methylene blue reversed this effect (Madison et ai, 
1967). These observations are consistent with the hypothesis that alcohol inhibits 
gluconeogenesis by lowering hepatic cytoplasmic redox potential, as a consequence of its 
metabolism. Such alterations in NADH:NAD+ have been demonstrated by direct measure-
ments (Smith and Newman, 1959). and indirectly by lactate: pyruvate ratios (Forsander et 
ai, 1965). Ethanol oxidation results in an increase in cytosolic and mitochondrial reduced 
nicotinamide-adenine-dinucleotide to oxidised-nicotinamide -adenine-dinucleotide (NADH 
: NAD +) ratios. The cytosolic alcohol dehydrogenase reaction, the major ethanol-
oxidising mechanism, results in acetaldehyde production. The acetaldehyde is further 
oxidised to acetate. These two reactions produce 2 mol NADH per mol of ethanol 
. oxidised (Fig. 3). 
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During ethanol metabolism the rate of NAD + reduction exceeds mitochondrial NADH 
oxidation, thus increasing the cytosolic NADH : NAD + ratio. The shift in redox potential 
would be expected to decrease the availability of substrates (pyruvate, alanine, glycerol) 
for gluconeogenesis. 
When fructose was added to the perfusion medium instead of pyruvate, glucose produc-
tion by the alcohol-treated livers was significantly increased. Since fructose is a non-
NAD + dependent precursor of glucose, glucose production in response to fructose would 
not be inhibited by an alteration of NADH : NAD + ratio. Other studies have also shown 
that ethanol does not inhibit glucose production from fructose (Kaden et ai, 1969; Field et 
ai, 1963; Madison, 1968; Tygstrup et ai, 1965). Our study also confirms that starvation is 
not a pre-requisite for ethanol inhibition of gluconeogenesis (Kreisberg et ai, 1971). 
In the presence of decreased glucose production, the increased lactate: pyruvate ratio in 
the experimental animal would suggest that the majority of the pyruvate was utilised to 
form lactate. However lactate levels were not increased in the experimental group. It is 
likely, therefore, that pyruvate entered another biochemical pathway. One possibility is 
that pyruvate was converted to L-alanine in the presence of an increased NADH : NAD + 
ratio. This contention is supported by the observation that methylene blue produced a 
rapid reversal of the inhibition of glucose production by alcohol in thi$ study. Other pos-
sibilities include the conversion of pyruvate to acetyle Co-A or malate (Fig 12). 
The study of Krebs et al (1969) and Kaden et al (1969), also on the effect of alcohol on 
gluconeogenesis using the isolated livers of fed and fasted rats, previously reported in-
creased lactate concentrations, increased lactate:pyruvate ratios and decreased pyruvate 
concentrations but the pyruvate conversion to glucose was not inhibited by ethanol when 
these livers were perfused with a medium containing pyruvate and ethanol, which is con-
trary to our findings. 
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Fig. 12 Pathways of hepatic gluconeogenesis. The specific enzymes upon which 
. gluconeogenesis is dependent are numbered within the large arrows. The NAD + -
dependent points in the pathway of gluconeogenesis are shown by the bold solid 
arrows. The direction of reactions in the presence of an elevated NADH:NAD + 
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In another situation when the livers of fed and fasted rats were perfused with a medium 
with or without ethanol, the following changes were observed. With livers from fed rats 
glucose was released from the liver into the perfusion medium. This release was slightly 
greater when ethanol was present. With livers from starved rats, no release of glucose was 
observed, and when ethanol was added a marked uptake of glucose from the medium was 
found. The lactate:pyruvate ratios in the perfusion medium increased from 10 to 87 with 
livers from fed rats and from 20 to 171 with livers from starved rats when the livers were 
perfused with ethanol in the medium. A simultaneous release of lactate and pyruvate into 
the medium occurred. The discrepancy in results of gluconeogenesis in the present ex-
periments was most probably due to the chronic alcohol treatment of the rats. 
The clearance of bromosulphthalein from plasma is a useful means of evaluating liver func-
tion. In the. present investigation a marked retention in perfusate and decreased biliary 
excretion of bromosulphthalein was observed in alcohol-treated rats. During the twenty 
minute perfusion, most of the dye was cleared from the perfusate with increased biliary 
excretion of the dye in the control animals whereas in the experiQ'lental animals, after an 
initial high clearance from perfusate, the concentration of the dye remained constant with 
decreased biliary excretion of the dye till the end of the experiment. 
The precise mechanism of increased bromosulphthalein retention i(l this setting is not 
clear. Previous studies in rats have shown that acute ethanol administration induces both 
a loss of glutathione from liver and an inhibition of glutathione synthesis (Speisky et ai, 
1985; Lauterberg et ai, 1984; Morton and Mitchell, 1985). Another study showed that 
patients with alcoholic liver disease had decreased hepatic glutathione compared to 
patients with liver disease unrelated to alcohol (Shaw et ai, 1983). Since the rate limiting 
step in the elimination of bromosulphthalein from plasma into bile of man and experimental 
animals is probably the conjugation of the dye with hepatic glutathione prior to its excre-
tion into the bile, it is possible that reduced glutathione levels were responsible for the 






Isoniazid is the hydrazide of isonicotinic acid, and has been the most widely used drug in the treat-
ment of tuberculosis with excellent therapeutic efficacy and good patient compliance (Gillman et 
ai, 1980; Maddrey and Boitnett, 1973; Zimmerman, 1978). 
Physical and Chemical Properties 
It occurs as a colourless, odourless, white crystalline powder with a taste slightly sweet at first and 
then bitter. Melting point 170°C to 174°C. Solubility ranges from 1 in 8 of water, 1 in 45 to 50 of 
alcohol, and 1 in 1000 of chloroform; very slightly soluble in ether. The molecular formula is 
C6H7N30 with molecular weight of 137,1 g. 
Structure of Isoniazid 
CONHNH 2 
Kinetic Data 
Isoniazid is readily absorbed from the gastrointestinal tract when administered either orally 
or parenterally. Peak concentrations appear In the blood 1 to 2 hours after dosing by 
mouth. The drug is not considered to be bound appreciably to plasma proteins and dif-
fuses into all body tissues and fluids including cerebrospinal fluid. 
Metabolism 
From 75% to 95% of a dose of isoniazid is excreted in the urine in 24 hours, mostly as me-
tabolites. The main excretory products are the result of enzymatic acetylation, 
(acetylisoniazid), and enzymatic hydrolysis, (isonicotinic acid). Small quantities of an 
isonicotinic acid conjugate, probably isonicotinyl glycine, one. or more isonicotinyl 
hydrazones and traces of N-methyl isoniazid are also detectable in urine. The drug is me-
tabolised principally by acetylation with a bi-modal distribution. T = 1 hr in fast acetylators, 
3hr in slow acetylators. The difference between fast and slow acetylators depends upon 
the amount of hepatic N-acetyl transferase present. It is known that the capacity for rapid 
acetylation is inherited as an autosomal dominant character while slow acetylation is 
thought to be transmitted by a recessive gene. The ratio of fast: slow acetylators is 40 : 60 
in Europe, 85 : 15 in Japan and 100 : 0 in Eskimos. These differences, have clinical conse-
quences. Increased drug toxicity including erythematosus-like syndrome may occur 
among slow acetylators; slow acetylators require low doses of isoniazid. Fast acetylators 
are more at risk from toxic effects referable to the metabolites of isoniazid. However it is 
important to emphasize that there is no conclusive evidence of a difference in therapeutic 
efficacy or in the incidence of toxicity related to the rate of acetylation of isoniaziq. 
Experimental Design 
Because of its potent bactericidal action combined with a low· incidence of serious adverse 
effects, isoniazid has been accepted as a first line agent in the treatment and prophylaxis 
of tuberculosis. The recommended daily dosage of this drug in adults is 5mg/kg with a 
maximum of 300mg; administration of therapeutic doses (and those exceeding the recom-
mended dose) of this compound has been complicated by liver damage (Maddrey, 1981; 
Martin and Arthaud, 1970). 
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The study of gluconeogenesis and bromosulphthalein clearance using the isolated liver perfusion 
model has been found to be a good method of evaluating the effect of toxic doses of drugs, eg 
ethanol on liver function. In this investigation, this model was used to determine the effects of 
isoniazid on liver function when the substance was administered to a group of rats for a 3 month 
period in a dose equivalent to two and a half times the recommended adult dose. 
Materials and Methods 
10 male Wistar rats (175 - 190 g) of the University of Natal inbred strain were kept in stainless steel 
cages with plastic bottoms. Each animal was individually earmarked for identification and ran-
domly assigned to either a control or an experimental group, each consisting of 5 rats. All the 
animals were fed on the same diet in the form of commercial rat cubes (Epol). 'Waterwas given ad 
libitum. The animals in the experimental group were given 2.5mg isoniazid per os daily for 90 days. 
The control group was untreated. The livers of experimental and control animals were perfused for 
75 minutes with a medium containing pyruvate (5QOumoles), a gluconeogenic precursor, and sub-
sequently these livers were perfused with a medium containing bromosulphthalein (1 .25mg/100g 
rat weight) for an additional 20 minutes. The animals were randomly chosen for perfusion. Serial 
specimens were obtained for analysis. 
Results 
Livers perfused for 2 hours showed no visible swelling or evidence of local or general ischaemia. 
The time course of glucose and lactate production by the livers of control and experimental 
animals, pyruvate concentrations and lactate: pyruvate ratios are shown in Tables 4a and 4b 
respectively and illustrated graphically (Figs. 13-16). 
Gluconeogenesis 
Pyruvate (500umoles) was added 10 minutes after the start of the perfusion; 290 umoles of 
pyruvate was removed from the perfusion medium in the control group compared to 330 umoles in 
the experimental group. The average lactate concentration was 2.99 mmoles/I at the end of the 
perfusion and formation was at an average rate of 0.04 mmoles/min per g wet weight of liver in the 
control group such that the lactate: pyruvate ratio was about 13 whereas the concentration was 
3.01 mmoles/I and formation was at an average rate of 0.1 mmolesjmin per g wet weight of liver 
such that the lactate:pyruvate ratio was about 18 in the expefimental group. Glucose formation 
was linear in both groups at a mean rate of formation of 0.09 mmoles/min g wet weight of liver in 
the control group compared to 0.02 mmoles/min per g wet weight of liver in the isoniazid-treated 
rats. The mean glucose concentrations at the end of perfusion was 5.42 mmolesjl in the control 
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group compared to 2.07 mmoles/I in the experimental group. The rate of glucose formation and 
glucose concentration were decreased and lactate:pyruvate ratios were increased in the ex-
perimental group compared to controls (p<0.05 for all comparisons except 30 and 60 minute 
lactate:pyruvate ratios). 
Bromosulphthalein 
Bromosulphthalein (1.25 mg/100g weight of rat) was added 80 minutes after the start of the perfu-
sion which continued for an additional twenty minutes. The time course of bromosulphthalein 
clearance from perfusate and biliary excretion of dye are shown in Table 4c. About 8.2% 
bromosulphthalein retention was observed in the control group while 51.6% was observed in the 
experimental group. The clearance of bromosulphthalein from perfusate (p<0.05; Fig. 17) and 




TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF CONTROL RATS (n=5) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150 ml; it decreased every 15 minutes by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.81 g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmolesjl) 
LACTATE 2.14 .±.0.06 2.56 ,±,0.20 2.41 ,±,0.16 2.94 .±.0.28 2.99 .±.0.19 
PYRUVATE 0.267 .±.0.01 0.215 .±.0.02 0.189 .±.0.01 0.186 .±.0.01 0.198 .±.0.01 
GLUCOSE 2.69 .±.0.04 3.35 .±.0.13 4.32 .±.0.31 4.92 .±.0.56 5.42 .±.0.76 
LACTATE: PYRUVATE ratios 8.20 ,±,0.20 13.00 .±.2.40 13.40 .±.1.70 16.20 .±.1.40 15.60 .±.1.00 
METABOLIC RATES (mmolesjmin per g wet weight of liver) 
GLUCOSE FORMATION 0.09 '0.14 0.09 0.07 
LACTATE FORMATION 0.06 -0.02 0.08 0.007 
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Table 4b 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF EXPERIMENTAL BATS (n=5) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150 ml; it decreased every 15 minutes by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.52 g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmolesjl) 
LACTATE 2.93 ,±,0.26 2.76 ,±,0.12 2.67 .±.0.16 2.96 .±.0.26 3.01 .±.0.14 
PYRUVATE 0.201 .±.0.004 0.191 .±.0.02 0.179 .±.0.01 0.159 .±.0.01 0.131 .±.0.01 
GLUCOSE 1.41 .±.0.09 1.54 .±.0.08 1.93 .±.0.27 2.09 .±.0.16 2.07 .±.0.30 
LACTATE:PYRUVATE ratios 14.63 .±.1 .30 15.95 .±.3.30 17.76 .±.2.40 19.61 .±.2.7 24.39 - .±.3.20 
METABOLIC RATES (mmoles/min per wet weight of liver) 
GLUCOSE FORMATION 0.02 0.06 0.02 0.003 
LACTATE FORMATION -0.03 -0.01 0.04 0.007 
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Table 4c 
TIME-COURSE OF BROMOSULPHTHALEIN CLEARANCE BY PERFUSED LIVERS OF CONTROLS AND EXPERIMENTAL ANIMALS 
The results are expressed as MEAN.±. SEM. SSP was added, at a dosage of 1.25 mg / 100 g weight of rat, to the perfusion medium. 
TIME (minutes) 0 5 10 15 20 
CONTROLS (5) 0.85 .±.0.01 0.60 .±.0.01 0.531 .±.0.01 0.20 .±.0.004 0.07 .±.0.008 
EXPERIMENTALS (5) 0.62 .±.0.01 0.38 .±.0.04 0.39 .±.0.008 0.34 .±.0.01 0.32 .±.0.008 
TIME-COURSE OF BILIARY EXCRETION OF BROMOSULPHTHALEIN 
TIME (minutes) 0 5 10 15 20 
CONTROLS (5) 0.09 .±.0.04 0.27 .±.0.12 0.49 .±.0.22 0.62 .±.0.28 0.79 .±.0.35 
EXPERIMENTALS (5) 0.20 .±.0.09 0.33 .±.0.15 0.31 .±.0.14 0.33 .±.0.15 0.38 .±.0.17 
41 
Fig. 13 Glucose concentrations deriVed from the perfusate of isolated perfused livers of 
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Fig. 14 Lactate concentrations derived from perfusate of isolated perfused livers of control 
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Fig. 15 Pyruvate concentrations derived from perfusate of isolated perfused livers of con-


















° 30 45 60 
TIME AFTER BEGINNING OF 
THE PERFUSION (MINJTES) 
a = p <0,005 b =p <0,05 
44 
Fig. 16 L8ctate:PyrtNate ratios derived from perfusate of isolated perfused livers of control 
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Fig. 17 Bromosulphthalein clearance derived from perfusate of isolated perfused livers of 
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c= NS 
Fig. 18 Biliary excretion of bromosulphthaJeln derived from bile of control and Isoniazid-treated rats . 
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Discussion 
Isoniazid has been an important agent in the treatment of tuberculosis since the early 1950's. 
Despite a few case reports of associated liver injury, it was initially considered relatively safe and 
was not generally regarded as an important hepatotoxin. In the early 1970's, however, an outbreak 
of isoniazid - associated hepatitis triggered a reassessment of its hepatotoxic potential, and the 
clinical, epidemiologic, and biochemical investigations of the ensuing decade leave little doubt that 
isoniazid can cause usually mild, but occasionally fatal, hepatic injury, although the possible 
mechanism or mechanisms involved remain in some doubt. Mild hepatotoxicity is a seemingly 
benign response occuring in approximately 10% of all the subjects receiving single drug isoniazid 
chemoprophylaxis (Bailey et ai, 1974; Mitchell et ai, 1975; Litt et ai, 1976; Mitchell et ai, 1975; 
Mitchell et ai, 1976). It may be entirely asymptomatic, and is most often characterised by a mild 
increase in serum transaminase activity during the first few months of treatment (Mitchell et ai, 
1975). In virtually all cases, the response appears to be transient and self limited and liver function 
tests revert to the normal despite continued administration of the drug. 
In this study, glucose production from the livers of isoniazid treated rats was decreased, indicating 
that gluconeogensis was impaired. The increased lactate: pyruvate ratio in the experimental livers 
would suggest that an alteration in redox state of cytosol may be the mechanism underlying the 
impaired gluconeogenesis. In contrast, the rate and amount of pyruvate utilization and of glucose 
production by the control livers were increased, indicating that the pyruvate that was added to the 
perfusion medium was utilized for the production of glucose. 
In the presence of decreased glucose production, increased lactate : pyruvate ratios (15 and 75 
minutes ratios only) in the isoniazid-treated animals would suggest that the majority of pyruvate 
was utilised to form lactate. However lactate levels were not increased in these experiments. It is 
likely therefore that pyruvate entered another biochemical pathway. One possibility is that pyruvate 
was converted to L-alanine. Other possibilities include the conversion of pyruvate to acetyl Co-A 
or malate (Fig 12). 
The study of Rubin et al (1952), also using supra-therapeutic doses of isoniazid (.17.5 mgjkg) in 
dogs, reported central nervous system dysfunction, including convulsions and jaundice (with 
marked fatty degeneration of liver) resulting when this dose was given to two animals, the 
symptoms appearing after two to four weeks. Benson et al (1952) also reported slight liver pathol-
.ogy in dogs which had received isoniazid 5 and 10 mgjkg. In another study involving 32 patients 
receiving 16 - 24 mgjkg, one developed convulsive seizures with subsequent encephalopathy and 
14 developed neuritis. The incidence of hepatic dysfunction was much less definite. Changes in 
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standard liver function tests appeared in approximately one half of the 17 patients studied; but 
were found on repeated testing in only 4 patients. While these changes were real, they were tran-
sient in every Case. Thus, a daily dosage of 17.5 mg/kg in dog and 20mg/kg in man apparently 
has a high degree of neural toxicity, but significant hepatic toxicity was not observed at this 
dosage in patients even though it had been observed in dogs. 
In the present investigation, a marked retention In perfusate and decreased biliary excretion of 
bromosulphthalein was observed in isoniazid - treated rats. During the 20 minute perfusion, most 
of the dye was cleared from perfusate in the control animals with increased biliary excretion of the 
dye; in experimental animals, after an initial high clearance, from perfusate, the concentration of 
the dye remained constant with decreased biliary excretion of the dye till the end of the experi-
ment. The decrease in bromosulphthalein clearance from the perfusate and the biliary excretion of 
the dye in isoniazid-treated rats was presumed to be as a result of depressed activities of some en-
zymes and altered permeability of cell membranes. 
This study demonstrates that isoniazid inhibits gluconeogenesis and bromosulphthalein clearance 
from perfusate and biliary excretion of the dye in rats when given in a dose two and a half times the 
recommended adult human dose. Whether or not prolonged supra-therapeutic doses of isoniazid 
will prove superior to conventional doses in tuberculous patients is uncertain at present but will be 
the subject of further study. The data available from the present and previous studies, suggests 
that it is inadvisable to prescribe doses of isoniazid beyond conventional dose as hepatic disor-






Numerous reports have been published showing rifampicin to be a potent antituberculous 
drug, comparable with isoniazid in its activity in both animals and humans (Cannetti et ai, 
1968; Pines, 1971). Rifampicin is an antibiotic derived from the family of rifamycins; it is 
produced by Streptomyces mediterranei and mainly used for its antituberculous action 
(Vall-Spinonsa et ai, 1970). Rifampicin is also a drug of choice for chemoprophylaxis of 
meningococcal disease and shows promise in the treatment of certain non-mycobacterial 
disease and as an adjunct in the treatment of leprosy. The fear of drug resistance has 
prevented its wider use, despite its excellent activity against staphylococci, some Gram-
negative bacilli and legionellae. Drug resistance can emerge quite rapidly if rifampicin is 
used alone. There has been a steady increase in the use of rifampicin to treat 
Staphylococcus epidermidis infections which are commonly extremely sensitive. In such 
cases, however, it is appropriate to combine rifampicin with another drug such as 
flucloxacillin, to reduce the risk of drug resistance. Rifampicin is also ~sed in the treatment 
. of legionnaire's disease. 
Physical and Chemical Properties 
Rifampicin is a tasteless, brick red to reddish-brown crystalline powder. It is a zwitterion 
and is soluble in organic solvents and in water at acidic pH. The molecular formula is 
C43H58N4012 with molecular weight of 823g. 
50 








Rifampicin is 'well-absorbed. The oral administration of rifampicin produces peak concentrations in 
plasma in 2 to 4 hours. Rifampicin is distributed throughout the body and is present in effective 
concentrations in many organs and body fluids including the cerebrospinal fluid. This is ex-
emplified by the fact that the drug may impart orange red colour to urine, faeces, saliva, sputum, 
tears and sweat. 
Metabolism 
It is partly metabolised in the liver by de-acetylation followed by glucuronidation to inactive metab-
olites and partly excreted into bile unchanged with consequent re-circulation. The rest is 
eliminated unchanged in the urine. T1 /2 = 3 hours. Biliary excretion increases progressively 
during the first 2 weeks of treatm~nt and T1 /2 shortens. 
Experimental Design 
Rifampicin has achieved first line status in the treatment of tuberculosis. The administration of 
therapeutic doses of this compound has been complicated by the development of hepatic damage 
in the form of hepatitis (Scheuer et ai, 1974). The recommended daily dosage of this drug in adults 
is 10mg/kg, with a maximum of 600mg. An investigation using the isolated rat liver perfusion tech-
nique was conducted to determine whether the administration of rifampicin, in doses exceeding 
those that are recommended, would affect gluconeogenesis and bromosulphthalein clearance by 
the liver. 
Materials and Methods 
12 male Wistar rats (190 - 200 g) of the University of Natal inbred strain were kept in stainless steel 
cages with plastic bottoms. Each was individually ear marked for identification and randomly as-
signed to either a control or an experimental group, each with 6 rats. All the animals were fed on 
the same diet in the form of commercial rat cubes (Epol). Water was given ad libitum. The animals 
in the experimental group were given 4 mg rifampicin per os daily for 90 days; the control group 
was untreated. The livers of control and experimental rats were perfused for 75 minutes with a 
medium containing pyruvate (500umoles), a gluconeogenic precursor . . 
Immediately after perfusion with the medium containing pyruvate, the livers of both the groups 
were perfused with a medium containing bromosulphthalein (1.25mg/100g rat weight) for an addi-
tional 20 minutes. The animals were randomly chosen for perfusion. Serial specimens were ob-
tained for analyses. 
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Results 
Evidence of satisfactory functioning of liver in this study was indicated by the absence of 
patchy colouring of the liver, swelling and formation of exudate on the surface of the liver 
after two hours of perfusion. The time course of glucose and lactate production by livers 
of control and experimental animals, pyruvate concentrations and lactate : pyruvate ratios 
are shown in Tables 5a and 5b respectively and illustrated graphically (Figs. 19-22). 
Gluconeogenesis 
When the livers of the control rats were perfused with a medium containing pyruvate (500 
umoles). there was an increase in glucose and lactate contents of the medium. Mean 
glucose concentration derived from the perfusate after 90 minutes of perfusion was 4.55 
mmoles/I and glucose formation was at an average rate of 0.07 mmoles/min per g wet 
weight of liver while lactate concentration was 2.63 mmoles/I and formation at an average 
rate of 0.002 mmoles/min per g wet weight of liver. The pyruvate concentration in the 
medium dropped by 300 umoles such that the lactate:pyruvate ratio was at a value of 
about 12. 
Similarly when the livers of rifampicin-treated rats were perfused witt\ medium containing 
pyruvate (500 umoles) there was a rapid increase in lactate and a steady but slow increase 
in glucose contents of the medium. Lactate concentration was 3.03 mmoles/I at the end 
of the perfusion with formation at an average rate of 0.02 mmoles/min per g wet weight of 
liver. The pyruvate content of the medium decreased by 385 umoles such that the 
lactate:pyruvate ratio was approximately 24. 
The glucose concentration was 1.78 mmoles/I and the formation was at an average rate of 
0.006 mmoles/min per g wet weight of liver. The rate of glucose formation and glucose 
concentration were decreased and lactate:pyruvate ratios increased in the experimental 
group compared to controls (p<0.05 for all comparisons). 
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Bromosulphthalein Clearance 
Bromosulphthalein was added, at a dosage of 1.25 mg/100g body weight of rat, 80 
minutes after the beginning of the perfusion which continued for an additional 20 minutes. 
The bromosulphthalein clearance from perfusate in the control and experimental group 
was similar. No biliary excretion of dye could be detected in the scanty bile collected. 
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Table 5a 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF CONTROL RATS (n=6) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150 ml; it decreased every 15 min by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.28 g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmoles/I) 
LACTATE 2.60 .±.0.33 2.65 .±.0.09 2.85 .±.0.08 2.43 .±.0.18 2.63 .±.0.06 
PYRUVATE 0.200 .±.0.01 0.212 .±.0.01 0.211 .±.0.01 0.210 .±.0.004 0.196 .±.0.004 
GLUCOSE 2.84 .±.0.10 3.05 .±.0.21 3.68 .±.0.23 3.57 .±.0.32 4.77 .±.0.65 
LACTATE:PYRUVATE ratios 13.30 .±. 1.9 12.67 .±.0.78 13.92 .±.0.98 11 .53 .±.0.72 13.43 .±.0.28 
METABOLIC RATES (mmoles / min per g wet weight of liver) 
GLUCOSE FORMATION 0.03 0.10 0.01 0.19 
LACTATE FORMATION 0.008 '0.03 -0.06 0.03 
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Table 5b 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF EXPERIMENTAL RATS (n=6) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150ml; it decreased every 15 minutes by 10ml. (removed for analysis). 
The livers had a mean wet weight of 6.18 g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmoles/I) 
LACTATE 2.58 .±.0.16 2.55 .±.0.24 2.73 .±.0.23 3.07 .±.0.07 3.03 .±.0.35 
PYRUVATE 0.110 .±.0.004 0.115 .±.0.004 0.108 .±.0.004 0.118 .±.0.008 0.135 .±.0.008 
GLUCOSE 1.99 ,±,0.22 1.83 .±.0.19 1.82 .±.0.17 1.86 .±.0.16 1.78 .±.0.19 
LACTATE:PYRUVATE ratios 23.61 .±. 1.9 22.26 ,±,2.2 25.16 .±. 1.9 26.73 .±.2.1 23.20 .±.3.7 
METABOLIC RATES (mmoles / min per g wet weight of liver) 
GLUCOSE FORMATION -0.02 -0.001 0.006 -0.01 
LACTATE FORMATION -0.004 0.03 0.06 -0.006 
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Table 5c 
TIME-COURSE OF BROMOSULPHTHALEIN CLEARANCE BY PERFUSED LIVERS OF CONTROLS AND EXPERIMENTAL ANIMALS 
The results are expressed as MEAN.±. SEM. SSP was added, at a dosage of 1.25 mg / 100g body weight, to the perfusion medium. 
TIME (minutes) 0 5 10 15 
CONTROLS (6) 0.84 .±.0.008 0.58 .±.0.02 0.467 .±.0.03 0.25 .±.0.01 0.05 





Fig. 19 Glucose concentrations derived from perfusate of isolated perfused livers of con-






















Fig. 20 Lactate concentrations derived from perfusate of isolated perfused livers of con-
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a = p <0,005 b= p <0,05 c= NS 
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Fig.21 Pyruvate concentrations derived from perfusate of isolated perfused livers of con-
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Fig. 22 Lactate:Pyruvate ratios derived from perfusate of isolated perfused livers of control 




























Rifampicin has achieved first line status in the treatment of tuberculosis because of its low 
toxicity and high therapeutic efficacy. It is metabolised in the liver mainly by de-acetylation 
followed by glucuronidation. 
In the present study, glucose production and pyruvate utilization were increased in control 
animals compared to experimental animals indicating that the pyruvate added to the perfu-
sion medium was utilized mainly for the production of glucose. In contrast the glucose 
production by rifampicin-treated animals was decreased compared with control animals 
indicating that gluconeogenesis was impaired. In the presence of decreased glucose 
production, the increased lactate: pyruvate ratios in the experimental animals would sug-
gest that the majority of the pyruvate was utilized to form lactate. However lactate levels 
were not increased in the experimental animals. It is likely therefore that pyruvate entered 
another biochemical pathway. One possibility is that pyruvate was converted to L-alanine. 
Other possibilities include the conversion of pyruvate to acetyl Co-A or malate. 
There was no difference between the 2 groups for bromosulphthalein clearance from per-
fusate; no biliary excretion of bromosulphthalein could be detected in the scanty bile col-
lected from livers of rifampicin-treated rats. 
Liver function and serum concentration of rifampicin, a highly cholephilic antibiotic, have 
been studied after the ingestion of a single dose of rifampicin in 12 patients and during 
treatment with 600 mg of rifampicin per day for 17 days in 8 patients. Rifampicin caused a 
considerable decrease in the bromosulphthalein plasma disappearance rate and a slight 
increase in bilirubin (Capelle et ai, 1972). This apparent competition between 
bromosulphthalein and bilirubin which involved mainly uptake, but also excretion by the 
liver cells was always rapidly reversible when treatment was discontinued. These workers 
conclude that on the basis of these findings, it is impossible to interpret a 
bromosulphthalein test during treatment with rifampicin; the bromosulphthalein test in a 
patient treated with rifampicin can only be interpreted 24h after rifampicin has been 
stopped. Since the present study was conducted while the rats were receiving rifampicin, 
it is not possible to draw any conclusions from the results of bromosulphthalein clearance. 
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The liver damage that follows rifampicin administration is believed to be idiosyncratic. 
However, in the present investigation, rifampicin administration in a dose equivalent to 2 
times the recommended adult dose for a 3 month period resulted in impaired 
gluconeogenesis in all the experimental rats. 
The information obtained from the study is inadequate. However, since therapeutic doses 
of rifampicin may be associated with hepatobiliary dysfunction, supra therapeutic doses of 






Paracetamol, a medication available over the counter without a prescription, is a major 
component of many formulations available for the relief of headaches, fever, coughs and 
cold. 
Physical and Chemical Properties 
It occurs as a crystalline powder or white odourless crystals with a bitter taste. Melting 
point ranges from 168°C to 172°C. The solubility of the substance varies with different sol-
vents. 
Kinetic Data 
Following oral ingestion, paracetamol is rapidly absorbed from the gastrointestinal tract 
and peak plasma concentrations are reached in 30-60 minutes. The drug is uniformly dis-
tributed throughout most body fluid and is only fractionally bound to plasma proteins 
(25%). It is primarily metabolised by conjugation with glucuronide or sulphate, and the 
plasma half life ranges between 1-3 hours. The molecular formula is Cs Hg N02 with 
molecular weight of 151 ,2g. 
6 4 
Structure of Paracetamol 
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Metabolism 
A number of drugs including paracetamol, a widely used non-narcotic analgesic, produce 
hepatotoxicity by generating chemically reactive metabolites which react indiscriminately 
with vital cellular macro molecules. In therapeutic doses paracetamol is metabolised, the 
major part being converted to glucuronide and sulphate conjugates and very little (5-10%) 
of the drug is excreted unchanged in the urine. (Fig. 23). A very small proportion (in the 
liver) is converted by hepatic microsomal enzymes to a highly unstable and potentially 
hepatotoxic metabolite, N-acetylimidoquinone, which is rapidly inactivated by conjugation 
with hepatic glutathione. Hepatic glutathione plays a vital role in protecting against 
peroxidative damage, detoxifying the reactive paracetamol metabolite by acting as a 
ligand to form a paracetamol glutathione conjugate or as a reducing agent to convert the 
reactive metabolite back to parent compound. The resulting paracetamol - glutathione 
conjugate is then excreted into the bile. 
However, after an overdose, the sulphation and glutathione pathways become saturated. 
The proportion excreted as conjugates decreases with the increasing dose of the drug. 
The depletion of hepato-cellular glutathione occurs because the rate of formation of the 
metabolite of drug exceeds the rate at which the liver can synthesise glutathione for con-
jugation. The reactive metabolite accumulates within the liver and arylates essential cell 
structures. 
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Fig 23. Possible mechanisms of hepatotoxicity from paracetamol. 
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It has also been demonstrated that paracetamol can undergo metabolism to a highly reac-
tive and electrophilic free radical. Free radicals are highly unstable and chemically reactive 
compounds beCause they contain an unpaired electron. Donation of this electron to 
oxygen leads to formation of highly reactive superoxide, and when a free radical comes 
into proximity with unsaturated lipids, as in cell membranes, it initiates a self-perpetuating 
peroxidative decomposition, with disruption of membrane structure and function. 
It is now recognised that paracetamol hepatotoxicity occurs not only in persons who in-
gest massive amounts of the drug but also in some individuals who ingest quantities in 
sub-therapeutic doses. 
Experimental Design 
Paracetamol is a widely used analgesic. Overdose with this compound results in 
hepatotoxicity which may be fatal. In vivo studies of glucose metabolism and 
bromosulphthalein clearance have shown that impaired gluconeogenesis and 
bromosulphthalein clearance often occurs after liver damage due to paracetamol over-
dose. Earlier studies have shown that in chronic alcoholics paracetamol hepatotoxicity 
occurs with therapeutic or near therapeutic doses of paracetamol (5eeff et ai, 1986; Mclain 
et ai, 1980; Johnson et ai, 1981). A recent report showed that in two patients, with a high 
daily alcohol consumption, liver damage exhibiting clinical and morphological features of 
paracetamol hepatotoxicity occurred; al~hough the patients took only therapeutic doses of 
paracetamol (Floren et ai, 1987). In order to test the hypothesis that the isolated liver per-
fusion technique could be a valuable means of assessing the effect of therapeutic doses of 
drugs on liver function, this investigation was conducted to determine the effects of 
therapeutic doses of paracetamol on gluconeogenesis and bromosulphthalein clearance 
using this technique. 
Materials and Methods 
24 male Wistar rats (170 - 1909) of the University of Natal inbred strain were kept in stain-
less steel cages with plastic bottoms. Each was individually earmarked for identification 
and randomly assigned to 3 groups, one control and 2 experimental, each with 8 rats. All 
the animals were fed on the same diet in the form of commercial rat cubes (Epol). Water 
was given ad libitum. The animals in the experimental groups were given 0.005g 
paracetamol per os daily for 90 days. 
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The control group was untreated. The livers of the control (Group A) and one experimen-
tal group (Group 8) were perfused for 75 minutes with a medium containing pyruvate 
(500umoles), agluconeogenic precursor, and subsequently the livers of control rats were 
perfused with a medium containing bromosulphthalein (1 .25mgj100g rat weight) for an 
additional 20 minutes. The second experimental group (Group C) which was reduced to 6 
because of the death of 2 rats during the course of the study, was perfused with a medium 
containing pyruvate (500umoles) and 1m1 10% solution of methylene blue and subse-
quently these livers were perfused with a medium containing bromosulphthalein 
(1.25mg/100g rat weight) for an additional 20 minutes. The animals were randomly 
chosen for perfusion. Serial specimens were obtained for analyses. 
Results 
The success of the isolated liver perfusion technique was judged mainly by the complete-
ness with which the blood was expelled from the liver as indicated by the quick fading of 
the organ's colour. The time-course of glucose and lactate production by the livers of 
control and experimental animals, pyruvate concentrations and lactate:pyruvate ratios are 
shown in Tables 6a and 6b respectively and illustrated graphically (Figs. 24-27). 
Gluconeogenesis 
Results of control and experimental perfusion with pyruvate (500 umoles) shows that livers 
of control rats shed appreciable amounts of glucose and lactate during 75 minutes of per-
fusion. The mean glucose concentration was 3.69 mmoles at the end of perfusion and the 
average rate of glucose formation was 0.07 mmoles/min per g wet weight of liver while the 
lactate concentration was 3.07 mmolesjl after 75 minutes of perfusion and the mean rate 
of lactate formation was 0.04 mmoles/min per g wet weight of liver. About 300 umoles of 
pyruvate were utilized such that the lactate:pyruvate ratio was at a value of about 12. 
In the experimental rats the mean glucose concentration obtained from perfusate was 1.95 
mmolesjl at the end of perfusion and the glucose formation was at an average rate of 0.03 
mmoles j min g wet weight of liver while the mean lactate concentration derived from the 
perfusate at the end of the perfusion was 4.34 mmolesjl and the rate of lactate formation 
was 0.06 mmolesjmin per g wet weight of liver. The experimental livers utilised about 350 
umoles of pyruvate such that the lactate:pyruvate ratio was about 30. 
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The rate of glucose formation and glucose concentration was decreased, lactate levels 
and lactate:pyruvate ratios were increased in the experimental groups compared to con-
trol (p<0.05 for all comparisons except 15 minute lactate levels). 
Glucose Formation 
1m110% methylene blue (a redox agent capable of oxidising NAOH to NAO+) was added 
at the start of perfusion which continued for 75 minutes. In two experiments, one with 
pyruvate plus methylene blue (0.78mmolesjl) and the other with pyruvate alone 
(1.95mmolesjl), glucose concentration was low in both experiments. Methylene blue did 
not overcome the paracetamol inhibition of pyruvate conversion to glucose. Methylene 
blue had no effect on glucose output, in fact even lower than that of pyruvate alone (p < 
0,05; Fig. 28). 
Bromosulphthalein Clearance 
Bromosulphthalein was added at a dosage of 1.25 mgj100g body weight of rat to the per-
fusion medium 80 minutes after the beginning of the perfusion. The time course of 
bromosulphthalein clearance from perfusate and the biliary excretion of the dye are 
shown in Table 6c. The percentage of bromosulphthalein retention in the perfusate of con-
trol animals was 8.3% while that of the paracetamol-treated group was 41.6%. 
Bromosulphthalein clearance from perfusate (p<0.005; Fig. 29) and biliary excretion of the 
dye (p<0.05; Fig. 30) were impaired in the experimental livers compared to controls. 
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Table 6a 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF CONTROL RATS (n=8) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150 ml; it decreased every 15 minutes by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.08g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmoles/I) 
LACTATE 1.84 .±.0.07 2.23 .±.0.22 2.38 .±.0.11 2.42 .±.0.12 3.07 .±.0.14 
PYRUVATE 0.235 .±.0.07 0.182 .±.0.01 0.191 .±.0.04 0.190 .±.0.04 0.205 .±.0.04 
GLUCOSE 2.14 .±.0.1 2.45 .±.0.09 2.78 .±.0.25 3.66 .±.0.36 3.69 .±.0.28 
LACTATE:PYRUVATE ratios 7.90 .±.0.38 13.57 .±.2.2 13.19 .±. 1.6 13.36 .±.1.4 15.51 .±. 1.5 
METABOLIC RATES (mmoles / min per g wet weight of liver) 
GLUCOSE FORMATION 0.05 0.05 0.14 0.004 
LACTATE FORMATION 0.06 0.02 0.006 0.10 
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Table 6b 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF EXPERIMENTAL RATS (n=8) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN .± SEM. The initial volume of the medium was 150 ml; it decreased every 15 min by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.01 g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmolesjl) 
LACTATE 2.71 ,±0.47 3.26 .±0.36 3.91 .±0.46 4.08 .±0.31 4.34 .±0.51 
PYRUVATE 0.115 .±0.003 0.120 .±0.01 0.134 .±0.01 0.129 .±0.01 0.123 .±0.01 
GLUCOSE 0.93 ,±0.14 0.99 .±0.18 1.20 .±0.17 1.19 ,±0.14 1.95 .±0.25 
LACTATE:PYRUVATE ratios 21.01 .±4.5 28.12 .±3.5 31.03 .±4.7 33.81 .±3.9 36.22 .±4.7 
METABOLIC RATES (mmoles j min per g wet weight of liver) 
GLUCOSE FORMATION 0.01 0.03 -0.001 0.1 
LACTATE FORMATION 0.09 0.11 0.03 0.04 
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Table 6c 
TIME-COURSE OF BROMOSULPHTHALEIN CLEARANCE BY PERFUSED LIVERS OF CONTROL AND EXPERIMENTAL ANIMALS 
The results are expessed as MEAN.±. SEM. SSP was added, at a dosage of 1.25 mg / 100g body weight, to the perfusion medium. 
TIME (minutes) 0 5 10 15 
CONTROLS (8) 0.84 .±.0.007 0.59 .±.0.01 0.51 .±.0.002 0.22 .±.0.007 0.07 
EXPERIMENTALS (6) 0.72 .±.0.06 0.31 .±.0.02 0.29 .±.0.02 0.31 .±.0.03 0.30 
TIME (minutes) 
































Fig. 24 Glucose concentrations derived from perfusate of isolated perfused livers of con-
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Fig. 25 Lactate concentrations derived from perfusate of isolated perfused livers of control 
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Fig. 26 PyrLNate concentrations derived from perfusate of isolated perfused livers of control and paracetamol-treated rats 
,2 
~ , 1 
'0 
E 
E 15 ...... , 
w 
I-




Il. 0 , 
,06 
; ~~:;)~ : :» 
o I [ ....... 1;>.'21 , ......•. 10>1 ,········ \ ".;\'1 1<·:·:·.b>\'1 , . . " "")] 
~ - 30 45 60 ~~ 
TIME AFTER BEGINNING OF 
THE PERFUSION (MINlfTES) 
a=p<0,005 
7 6 
Fig. 27 Lactate:Pyruvate ratios derived from perfusate of "isolated perfused livers of con-
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Fig. 28 The effect of methylene blue, a redox agent, on glucose concentrations derived 
from perfusate of isolated perfused livers of control (experimental group 1) and 
























Fig. 29 Bromosulphthalein clearance derived from perfusate of isolated perfused livers of 





























5 10 15 
TIME AFTER BEGINNING 
THE PERFUSION (MINUTES) 
a=p<0,005 
79 
Fig. 30 Biliary excretion of bromosulphthaleln derived from bile of control and paracetamol-treated rats . 
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Discussion 
Paracetamol, a widely used analgesic, is known to cause acute hepatic necrosis (Henry 
and Volans, 1984; Meredith et ai, 1986), which is sometimes fatal in adults when taken in 
overdose (Clark et ai, 1973; Davidson and Eastham, 1966; Koch-Weser, 1976; Prescott 
and Wright, 1973). The clinical course of patients with liver damage following paracetamol 
overdosage is often complicated by the development of hypoglycaemia 24 - 72 hours after 
overdose (Record et ai, 1975). In a study of glucose metabolism in 14 patients with liver , 
damage due to paracetamol overdose, impaired gluconeogenesis was suggested by mild 
fasting hypoglycaemia in 4 patients and raised fasting blood lactate levels. It is also recog-
nised that in some patients chronic ingestion of paracetamol, even in low doses, may 
produce hepatic necrosis and hepatitis long after the drug has been discontinued (Barker 
et ai, 1977; Bonkowsky et ai, 1978; Canalese et ai, 1981; Johnson and Tohman, 1977; 
Neuberger and Davis, 1981). The recommended maximum dose of paracetamol is 4 g 
daily. 
In this study paracetamol, which was given in therapeutic doses, was found to inhibit 
gluconeogenesis. This was evidenced by decrease in glucose levels, an increase in the 
concentration of lactate and an increase in the lactate : pyruvate ratio in the perfusion 
medium of the experimental animals. The decreased glucose prQduction by the ex-
perimentallivers which occurred pari passu with an increased pyruvate utilization indicates 
that pyruvate in these animals was used for the production of lactate. In contrast the rate 
and amount of glucose production and of pyruvate utilization were increased in the control 
group indicating that pyruvate was used mainly for the production of glucose. 
The increased lactate : pyruvate ratio, which reflects the increase in NADH : NAD + ratio, 
suggests that an alteration in the redox potential of the cytosol was responsible for the im-
paired gluconeogenesis. However when methylene blue (a redox dye capable of oxidising 
NADH to NAD + ) was added to the perfusion medium, the glucose output remained low in 
the experimental group. It is likely therefore that impaired gluconeogenesis is not directly 
related to an alteration in the NADH : NAD + ratio. It is possibly related to the non 
availability of oxaloacetate or the impairment of the activity of key enzymes of 
gluconeogenesis. ( 1) pyruvate carboxylase, 2) phosphoenol pyruvate carboxykinase, 3) 
fructose 1 ,6-diphosphatase and 4) glucose-6-phosphatase; Fig. 12). 
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In the present investigation, in rats treated with therapeutic doses of paracetamol, a 
marked bromosulphthalein retention in perfusate and decreased biliary excretion of 
bromosulphthalein was observed. During the twenty minute perfusion, most of the dye 
was cleared from perfusate with increased biliary excretion of the dye in the control 
animals whereas in the experimental animals after an initial high clearance from perfusate, 
concentration of the dye remained constant with concomitant decreased biliary excretion 
of the dye till the end of the experiment. The rate limiting step in the elimination of 
bromosulphthalein from plasma into the bile of man and experimental animals is probably 
the conjugation of the dye with hepatic glutathione (Combes, 1965). 
Previous studies in rats have shown that impaired plasma clearance of bromosulphthalein 
is associated with low hepatic concentration of glutathione which results from the over-
dose with paracetamol (Mitchell et ai, 1973). It has also been reported that toxic doses of 
para-cetamol suppress hepatic glutathione synthesis. It is likely therefore, that the impaired 
bromosulphthalein clearance from perfusate in this study was related to reduced 
glutathione levels. 
However low concentration of hepatic glutathione are not soley responsible for the im-
paired bromosulphthalein clearance observed in rats. Another study has shown that the 
activity of glutathione transferase was also diminished in animals pre-treated with large 
doses of paracetamol (Davis et ai, 1975). In addition to impairment of hepatic uptake and 
conjugation of the dye, paracetamol markedly inhibits biliary excretion of the dye, and this 
is manifested both at therapeutic and hepatotoxic doses of the drug in man (Davis et ai, 
1975). Studies in rats indicate that interaction between paracetamol and 
bromosulphthalein is at the canalicular membrane level, and appears to be competitive 
(Davis et ai, 1975). 
The present study demonstrates that paracetamol, when administered chronically in doses 
equivalent to therapeutic doses in the aqult human, impairs hepatic function as evidenced 
by impaired gluconeogenesis and bromosulphthalein clearance, from perfusate and 
decreased biliary excretion of the dye and since it is difficult to apply animal data to 
primates; it is proposed to extend this study to include humans. Paracetamol is cdn-
sidered to be a safe analgesic but should the results obtained coincide with that of man; it 
would be important to monitor liver function tests in patients treated chronically with 






The industrial solvent n-Hexane has been implicated as the agent responsible for the 
development of peripheral neuropathy in a variety of industrial workers and also in in-
dividuals who habitually inhale glue vapours for their euphoric properties. In view of the 
importance of n-Hexane to industry and the problem of glue-sniffing among the younger 
generation, the present study was carried out to investigate the chronic effects of the pure 
compound on experimental animals. The development of distinctive hepatic damage is 
reported for the first time. 
Physical and Chemical Properties 
Hexane is a colourless, transparent, non-volatile, highly inflammable liquid with a charac-
teristic odour. It is insoluble in water, soluble in dehydrated alcohol, miscible with 
chloroform, ether and most fixed and volatile oils. Vapour-air mixture is explosive. Boiling 
point ranges (95%) from 6i'C to 70°C. Weight per ml at 20°C is 0.66Qg to 0.670g. 
Metabolism 
Hexane, a fraction from petroleum at 6i'C to 70°C, is metabolised to 2,5 - hexanedione 
before exerting its hepatotoxic effect. 
Structure of Hexane 
H H H H H H 
I I I I I I 
H--C--C--C--C--C--C--H 
I I I I I I 
H H H H H H 
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Experimental Design 
Glue and benzine, solvents which contain hexane in high concentrations, are often inhaled · to 
produce a state of euphoria. The toxic effects of hexane on the nervous system are well known. In 
order to determine the influence of hexane on liver function and morphology, the effects of hexane 
on gluconeogenesis and bromosulphthalein clearance were studied using the isolated liver perfu-
sion model and hepatic histology was examined using standard methods. 
Materials and Methods 
20 male Wistar rats (170 -180 g) of the University of Natal inbred strain were individually earmarked 
for identification and randomly assigned to 4 groups and kept in stainless steel cages with plastic 
bottoms. 3 groups were given subcutaneous injections of 0.2 ml hexane in olive oil (1:1vjv) and 
the control group 0.2 ml olive oil daily for 90 days. The livers of the control group and one of the 
experimental group were perfused for 75 minutes, with a medium containing pyruvate 
(500umoles), a gluconeogenic precursor, and subsequently these livers were perfused with a 
medium containing bromosulphthalein (1.25mgj100g rat weight) for an additional 20 minutes, 
while those of the 2nd group were perfused for 75 minutes with a medium containing pyruvate 
(500umoles) and 1 ml 10% solution of methylene blue (a redox dye capable of oxidising NADH to 
NAO+). The animals were randomly chosen for perfusion. Serial specimens were obtained for 
analysis. The livers of the third experimental group were subjected to histological examination. 
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Results 
The results obtained indicate that the method of perfusion is satisfactory for the study · of 
gluconeogenesis from pyruvate as the observed rates were higher than the normal rates measured 
in vivo. The time course of glucose and lactate production by the livers of control and hexane-
treated rats, pyruvate concentrations and lactate:pyruvate ratios are shown in Tables 7a and 7b 
respectively and illustrated graphically (Figs. 31-34). 
Gluconeogenesis 
\ 
Pyruvate (500 umoles) was added ten minutes after the start of perfusion; 295 umoles of the added 
pyruvate was utilized after 75 minutes of perfusion by the control livers. Mean glucose concentra-
tion was 5.75 mmoles/I at the end of perfusion with glucose formation at an average rate of 0.07 
mmoles/min g wet weight of liver. Lactate concentration was 3.12 mmoles/I and the average rate 
of lactate formation was 0.06 mmoles/min per g wet weight of liver such that the lactate:pyruvate 
ratio averaged 12. 
Similarly in the hexane-treated rats, after 80 minutes of perfusion 340 umoles of pyruvate was 
utilised. The glucose concentration was 1.46 mmoles/I and the average glucose formation rate 
was 0.01 mmoles/min per g wet weight of liver. Lactate concentration was 2.83 mmoles/I and the 
average rate of formation was 0.01 mmoles/min per g wet weight of liver such that the 
lactate:pyruvate ratio averaged 18. 
Glucose Formation 
1ml 10% methylene blue (a redox agent capable of oxidising NAOH to NAO+) was added at the 
start of the perfusion. The glucose concentration obtained in the group perfused with -pyruvate 
and methylene blue (1.34 mmoles/I) and pyruvate alone (1.46 mmoles/I) was more or less similar. 
Methylene blue had no effect on glucose output in the hexane-treated group (Fig. 35). 
The rate of glucose formation and glucose concentration was decreased, ladatelevels and 
lactate:pyruvate ratio increased in the experimental animals compared to controls (p<O.05 for all 
comparisons except 60 and 75 minute lactate levels). 
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Bromosulphthalein Clearance 
Bromosulphthalein was added at a dosage of 1.25 mg/100g body weight of rat 75 minutes 
after beginning of the perfusion. The time course of bromosulphthalein clearance from 
perfusate and biliary excretion of dye are shown in Table 7c. The bromosulphthalein per-
centage retention was 10.5% in the control group compared to 41.26% in the experimental 
group. Bromosulphthalein clearance from perfusate (p<0.05; Fig. 36) and biliary excretion 
of the dye (p<0.05 for all comparisons except the 5 minute biliary excretion; Fig. 37) were 
impaired in the hexane-treated rats. 
Microscopy 
Histological examination of liver biopsy specimens from hexane-treated rats revealed 
severe fatty change (Fig. 38). 
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Table 7a 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF CONTROL RATS (n=5) 
UNDER AEROBIC CONDITIONS (500 umoles of pyruvate added to perfusion medium). 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150 ml; it decreased every 15 minutes by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.05g. 
TIME (minutes) 15 30 45 60 75 
CONC. OF METABOLITE 
(mmolesjl) 
LACTATE 1.52 .±.0.21 2.31 .±.0.07 2.66 .±.0.19 2.98 .±.0.21 3.12 .±.0.33 
PYRUVATE 0.204 .±.0.O1 0.196 .±.0.01 0.210 .±.0.004 0.195 .±.0.01 0.201 .±.0.004 
GLUCOSE 3.87 .±.0.30 4.35 .±.0.31 4.80 .±.0.46 5.24 .±.0.54 5.75 .±.0.49 
LACTATE:PYRUVATE ratios 7.73 .±. 1.5 11.95 .±.0.88 12.78 .±. 1.20 15.44 .±.1.4 15.51 .±.1.6 
METABOLIC RATES (mmoles j min per g wet weight of liver) 
GLUCOSE FORMATION 0.08 {J.07 0.07 0.08 
LACTATE FORMATION 0.13 0.06 0.05 0.02 
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Table 7b 
TIME-COURSE OF THE PRODUCTION OF LACTATE, AND GLUCOSE BY PERFUSED LIVERS OF EXPERIMENTAL RATS (n=5) 
UNDER AEROBIC CONDITIONS (5~O umoles of pyruvate added to perfusion medium) 
The results are expressed as MEAN.±. SEM. The initial volume of the medium was 150ml; it decreased every 15 minutes by 10 ml. (removed for analysis). 
The livers had a mean wet weight of 6.01 g. 
TIME (minutes) 










.±. 1.5 16.3 
METABOLIC RATES (mmoles/ min per gwet weight of liver) 
GLUCOSE FORMATION 0.03 









45 60 75 
.±.O.OS 3.12 .±.0.20 2.83 ,±,0.19 
.±.O.OOS 0.172 .±.0.01 0.166 .±.0.01 
,±,0.12 1.2S .±.0.15 1.46 .±.0.16 
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Fig. 31 Glucose concentrations derived from perfusate of isolated perfused livers of con-
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Fig. 32 Lactate concentrations derived from perfusate of isolated perfused livers of control 
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\ 
Fig. 33 Pyruvate concentrations derived from perfusate of isolated perfused livers of con-
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Fig. 34 Lactate:Pyrwate ratios derived from perfusate of isolated perfused livers of con-
trol and hexane-treated rats 
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Fig. 35 The effect of methylene blue, a redox agent, on glucose concentrations derived from perfusate of Isolated perfused livers of control 
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Fig. 36 Bromosulphthalein clearance derived from perfusate of isolated perfused livers of 
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Fig. 37 Biliary excretion of bromosulphthalein derived from bile of control and hexane-treated rats . 
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Fig. 38 Fatty change In hexane-treated rats x 450 
Hepatocytes showing macro and micro vesicular fatty change 
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Discussion 
A wide variety of substances have been abused by sniffing or inhalation in order to produce a state 
of euphoria (Anderson et ai, 1982; Garriot and Petty, 1980; Kringsholm, 1980). Solvents in 
adhesives are the commonest, hence the term "glue sniffing", but many other substances are used 
including petrol, cleaning fluids, aerosol propellents, fire extinguishers and butane. Solvent or 
volatile substance abuse is therefore a more descriptive term. 
The method of inhaling may include pouring or squirting the substance onto a rag and inhaling 
from the rag, or pouring or squirting the substance into a jar or plastic bag and then inhaled. 
Sometimes the plastic bag may be placed over the head to ensure a high concentration of the sub-
stance. 
Benzine, a petroleum product consisting principally of hexane and n-pentane is bought freely by a 
large number of black children in Natal and sniffed to produce a state of euphoria. Glues contain-
ing hexane are also inhaled for this purpose. Long term inhalation of hexane has resulted in the 
development of progressive and predominantly motor polyneuropathy. 
Most reports on solvent abuse are concerned with effects on the nervous system; little attention 
has been paid to other organs such as the liver. Some forms of solv~nt abuse may result in direct 
hepatotoxicity. A commercial cleaning fluid which contained trichloroethylene was at one time 
popular with solvent abusers. Baerg et al (1970) reported that this agent caused acute 
centrilobular necrosis progressing to centrilobular fibrosis, and permanent disturbance of liver ar-
chitecture following repeated exposure. Another report describes a 45 yr old man who presented 
with intermitttent epistaxis and impaired liver function several days after his loghouse was coated 
with butyl caulk containing petroleum distillate and toluene (National Institute for Occupational 
Safety and Health report, 1982). Conroy et al (1984) reported transient ground glass hepatocellular 
change following a period of glue sniffing in a patient with underlying benign recurrent cholestatic 
jaundice. They postulate that the toluene base in glue was responsible for hepatotoxicity. There 
are no reports of liver damage resulting from hexane abuse. 
In this study hexane was found to inhibit gluconeogenesis. This was evidenced by decrease in 
glucose levels, an increase in the concentration of lactate and an increase in the lactate: pyruvate 
ratios in the perfusion medium of experimenteli animals. The rate arid the amount of glucose 
production and of pyruvate utilzation was increased in the control group indicating that the 
pyruvate was used mainly for the production of glucose .. In contrast, the decreased glucose 
production by the experimental livers which occurred in the presence of increased pyruvate 
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utilization indicates that the pyruvate in these animals was used for the production of lactate. The 
increased lactate : pyruvate ratio, which reflects the increase in the NADH : NAD + ratio, suggests 
that an alteration in the redox potential of the cytosol was responsible for impaired 
gluconeogenesis. However, when methylene blue (a redox dye capable of oxidising NADH to 
NAD +) was added to the perfusion medium, the output of glucose remained low in the experimen-
tal group indicating that the impaired gluconeogenesis was not directly related to the change in 
the NADH : NAD+ ratio. It is probably related to the non availability of oxaloacetate or the impair-
ment of the activity of key enzymes of gluconeogenesis. [ 1) pyruvate carboxylase, 2) phos-
phoenol pyruvate carboxykinase, 3) fructose 1,6-diphosphatase and 4) glucose-6-phosphatase, 
Fig. 12). 
In the present investigation a marked retention of bromosulphthalein in perfusate with decreased 
biliary excretion of the dye was observed in the hexane-treated rats; after an initial high clearance, 
the concentration of th dye in the perfusate remained constant with decreased biliary excretion of 
the dye till the end of the experiment. Most of the dye was cleared from perfusate and into the bile 
in the control animals during the 20 minutes of perfusion. Our data suggest that in the isolated 
liver, hexane is capable, in toxic doses, of interfering with bromosulphthalein clearance from per-
fusate and the biliary excretion of the dye. The mechanism is presumed to be canalicular with 
transport defects in the hepatic cell. Histological examination of liver biopsy specimens from the 
hexane -treated rats revealed severe fatty change. 
This study demonstrates that rats intoxicated by repetitive subcutaneous injections of pure hexane 
develop biochemical and pathological evidence of liver damage. Because of the difficulty in 
monitoring the dose of hexane used during sniffing by humans, the dose that was selected for this 
investigation was identical !o that which resulted in the degeneration in the central and peripheral 
nervous system in an earlier experimental study involving rats (Schaumburg and Spencer, 1976). 
The fact that neurotoxicity has been documented in man, supports the view that this model is 
relevant to man (Clark and Tinston, 1982). Greater awareness of the risk of hepatotoxicity follow-
ing hexane is needed. 
Since benzine and glues have a fairly high concentration of hexane, an important cause of central 
and peripheral nervous system and liver damage, and since their abuse is common among school 
children every effort must be made to combat this form of solvent abuse through an educational 
programme involving the school and the media. 
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I CHAPTER 8 
CONCLUSION 
CONCLUSION 
This study was performed to determine whether the isolated rat liver perfusion technique 
. could be used to measure the effect on liver function of therapeutic and supra-therapeutic 
doses of various drugs; some of which have been reported to be hepatotoxic in man. Al-
cohol and hexane were administered in toxic doses, rifampicin and isoniazid in high doses 
and paracetamol in therapeutic doses. Liver function was assessed by studying 
gluconeogenesis and bromosulphthalein clearance. The results obtained indicate that this 
technique is very satisfactory for this purpose. 
Evidence of satisfactory functioning of the liver in this study was indicated by the absence 
of patchy colouring of the liver and swelling and formation of exudate on the surface after 
two hours of perfusion. Glucose synthesis was well maintained over two hours and the 
concentrations obtained were higher than those reported using other liver perfusion tech-
niques (Garcia et ai, 1966; Eisenstein et ai, 1966) and several times higher than in liver 
slices (Hems et ai, 1966). 
Although the liver remained in situ, it was completely separated from other tissues, and the 
delay and trauma associated with removal from body and cannulation were avoided. 
A major advantage of the modified method of perfusion is the shorter duration in the inter-
ruption of circulation, the interruption period being about three minutes in this study. In 
contrast Schimassek (1963) noted that after seven to nine minutes period during which the 
circulation was interrupted the concentration of lactate in the liver rose eightfold. Restora-
tion to the initial state required about thirty minutes. A further advantage was the use of 
human red blood cells from the blood bank instead of rat blood because of the cost in-
volved and the elimination of blood glycolysis. 
All the drugs studied were found to inhibit gluconeogenesis. This was shown by a 
decrease in glucose levels and an increase in lactate : pyruvate ratios in the perfusion 
medium of experimental livers. The decreased glucose production by the experimental 
livers which occurred pari passu with an increased pyruvate utilization indicates that in 
~hese animals pyruvate was used for the production of other compounds such as lactate. 
In contrast glucose production and pyruvate utilization were increased in the control 
groups indicating that pyruvate was used mainly for the production of glucose. 
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In the ethanol group impaired gluconeogenesis was probably due to a change in the 
NAOH : NAO+ ratio; when methylene blue was introduced in the perfusion medium of this 
group the output of glucose was high. Impaired gluconeogenesis in the paracetamol and 
hexane-treated group was probably related to the non availability of oxaloacetate or the 
impairment of the activity of key enzymes involved in gluconeogenesis; when methylene 
blue was added to the perfusion medium of these animals the glucose output remained 
low. 
Except for the rifampicin study bromosulphthalein clearance was impaired in all the ex-
perimental groups. Histological examination of liver tissue obtained from the hexane-
treated animals demonstrated severe fatty change. 
In conclusion this study demonstrates: 
i) the isolated rat-liver perfusion technique is a valuable method of evaluating the ef-
fects of therapeutic and supra-therapeutic doses of drugs in vitro 
ii) that rifampicin and isoniazid in supra-therapeutic doses and paracetamol in 
therapeutic doses alter liver function in rats. 
Since the observations in the alcohol-treated rats are in keeping with those noted in man 
viz. that hypoglycaemia may complicate alcohol excess, no further studies using this com-
pound are planned. 
The following questions that arise from the present investigation, will need to be answered 
in future studies: 
i) What are the effects of therapeutic doses of rifampicin and isoniazid on liver func-
tion when using the isolated rat-liver perfusion technique (The present study in-
volved approximately doses twice the normal daily dosage) 
ii) What are the effects of a) chronic administration of therapeutic doses of 
paracetamol, and b) hexane abuse on liver function in man. 
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THE EFFECT OF THERAPEUTIC DOSES OF PARACETAMOL ON LIVER FUNCTION 
IN THE PERFUSED RAT LIVER. 
Khedun SM, Maharaj B, Leary WP. 
Department of Experimental and Clinical Pharmacology, Natal Medical School, Durban. 
Background 
Paracetamol, a widely used analgesic, can produce hepatic damage which can be fatal 
when taken in overdose. In some patients chronic ingestion of paracetamol, even in 
therapeutic doses, may produce hepatic necrosis and hepatitis. 
Aim 
This study was conducted to determine the influence of therapeutic doses of paracetamol 
on liver function (gluconeogenesis and bromosulphthatlien clearance) in the rat. 
Methods 
Three groups of rats were studied; those in the two experimental groups were given 0.005 
g paracetamol per os daily for 90 days. The isolated liver perfusion technique was used in 
the study. The livers of the control and one of the experimental groups were perfused with 
a medium containing pyruvate, a substrate for gluconeogenesis. A perfusion medium con-
taining both pyruvate and methylene blue, a redox agent capable of oxidising NADH to 
NAD +, was used in the second experimental group. Serial specimens were obtained for 
analysis. 
Results 
In the experimental livers glucose production was decreased, lactate production was in-
creased, pyruvate ratios were increased, methylene blue had no effect on glucose produc-
tion, and bromosulphthalein clearance was impaired. 
Conclusion 
This study demonstrates that paracetamol, when administered over a prolonged period in 
doses equivalent to therapeutic doses in adult humans, impairs function of the isolated 
perfused rat liver as evidenced by impaired gluconeogenesis and bromosulphthalein 
clearance. 
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THE EFFECT OF HEXANE ON LIVER FUNCTION AND LIVER MORPHOLOGY IN THE 
RAT. 
Khedun SM, Maharaj B, Leary WP. 
Department of Experimental and Clinical Pharmacology, Natal Medical School, Durban. 
Background 
Little attention has been paid to the possible effect of solvent abuse on the liver. 
Aim 
This study was conducted to determine the influence of hexane, one of the major com-
ponents of benzine and glue, on liver function (bromosulphthalein clearance and 
gluconeogenesis) and liver morphology in rats. 
Methods 
Four groups of rats were studied; three groups were given subcutaneous injections of 
O.2ml hexane daily for 90 days. The effects of hexane on gluconeogenesis and 
bromosulphthalein clearance were studied using the isolated liver perfusion technique. 
The livers of control group and one experimental group were perfused with a medium con-
taining pyruvate, a substrate for gluconeogenesis, while those of the. second group were 
perfused with a medium containing pyruvate and methylene blue (a redox agent capable 
of oxidising NADH to NAD+). Serial specimens were obtained for analysis. The livers of 
the third experimental group were subjected to histological examination using standard 
methods. · 
Results 
In the hexane-treated livers bromosulphthalein clearance was impaired, glucose and 
pyruvate concentrations were decreased, lactate concentrations and lactate : pyruvate 
ratios were increased. Methylene blue had no effect on glucose production. In addition 
severe fatty change was noted in the experimental livers. 
Conclusion 
This study demonstrates that hexane is hepatotoxic; it alters liver function 
(bromosulphthalein clearance and gluconeogenesis were impaired) and produces his-
tological changes which are indicative of hepatic damage. In addition to central and 
\ 
peripheral nervous system damage, it is likely that hexane abuse could also result in 
hepatotoxicity in humans. This hypothesis needs to be confirmed. Educational 
programmes designed to discourage abuse of benzine and glue are urgently needed. 
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THE EFFECT OF SUPRA-THERAPEUTUC DOSES OF ISONIAZID ON LIVER FUNC-
TION INTHE PERFUSED RAT LIVER. 
Khedun SM, Maharaj B, Leary WP. 
Department of Experimental and Clinical Pharmacology, Natal Medical School, Durban. 
Background 
Isoniazid has been the most widely used drug in the treatment of tuberculosis with excel-
lent therapeutic efficacy and good patient compliance. 
Aim 
This study was conducted to determine the influence of supra-therapeutic doses of 
isoniazid on liver function (gluconeogenesis and bromosulphthalein clearance from per-
fusate and biliary excretion of the dye) in the rat. 
Methods 
Two groups of rats were studied; those in the experimental group were given 2.5 mg 
isoniazid per os daily for 90 days. The effects of isoniazid on gluconeogenesis and 
bromosulphthalein clearance from perfusate and biliary excretion of the dye were studied 
using the isolated liver perfusion model. The livers of the control and the experimental 
group were perfused with a medium containing pyruvate, a substrate fro gluconeogenesis, 
and subsequently these livers were perfused with a medium containing bromosulphthalein. 
Serial specimens were obtained for analysis. 
Results 
In the isoniazid-treated livers glucose and pyruvate concentrations were decreased, lac-
tate concentrations and lactate:pyruvate ratios were increased, and bromosulphthalein 
clearance from perfusate and biliary excretion of the dye was impaired. 
Conclusion 
This study demonstrates that isoniazid, when administered over a prolonged period in 
doses equivalenUo two times the therapeutic dose in acjult humans, impairs the function 
of the isolated perfused rat liver as evidenced by impaired gluconeogenesis and 
bromosulphthalein clearance from perfusate_and biliary excretion of the dye. 
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APPENDIX A 
CONSTITUENTS OF 1 UTRE PERFUSION MEDIUM: 
NaCI 6.9g 
KCL 303.9 mg 
KH2P04 157.7 mg 
MgS04 292.3 mg 
cac~ 115.4 mg 
NaHC03 2.1 9 
pH adjusted to 7.4 
APPENDIX 8 
GLUCOSE CONCENTRATIONS IN CONTROL AND ALCOHOL·TREATED RATS 
CONTROLS 
Time in Minutes 
No. 15 30 45 60 75 
1. 2.65 3.47 3.55 5.64 6.84 
2. 2.83 3.21 4.52 4.85 5.62 
3. 2.87 4.43 4.53 4.32 6.65 
4. 3.79 3.59 4.17 4.28 6.41 
5. 3.29 4.28 7.51 7.51 8.17 
6. 2.85 3.15 4.12 5.89 4.31 
X 3.05 3.69 4.73 5.42 6.33 
SEM 0.17 0.22 0.57 0.49 0.52 
EXPERIMENTALS 
1. 1.50 1.90 2.90 3.10 1.50 
2. 1.30 1.70 1.70 1.90 2.00 
3. 1.20 1.10 1.60 2.30 2.00 
4. 1.30 1.10 1.80 1.80 2.00 
5. 1.20 1.70 0.90 1.80 1.80 
6. 1.20 1.50 1.60 1.90 2.50 
X 1.28 1.50 1.75 2.13 1.97 
SEM 0.04 0.13 0.26 0.20 0.13 
THE EFFECTS OF METHYLENE BLUE, A REDOX AGENT, ON GLUCOSE 
CONCENTRATIONS IN CONTROL (EXPERIMENTAL GROUP 1) AND ALCOHOL-
TREATED RATS (EXPERIMENTAL GROUP 2) 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 1.50 1.90 2.90 3.10 1.50 
2. 1.30 1.70 1.70 1.90 2.00 
3. 1.20 1.10 1.60 2.30 2.00 
4. 1.30 1.10 1.80 1.80 2.00 
5. 1.20 1.70 0.90 1.80 1.80 
6. 1.20 1.50 0.60 1.90 2.50 
X 1.28 1.50 1.75 2.13 1.97 
SEM 0.04 0.13 0.26 0.20 0.13 
EXPERIMENTALS 
1. 8.10 20.30 10.2 9.50 9.70 
2. 6.60 4.80 4.80 4.30 7.90 
3. 8.70 5.20 18.70 14.40 23.00 
4. 13.40 8.10 3.40 9.90 4.30 
5. 2.20 5.20 10.80 10.10 9.00 
6. 7.60 5.50 14.20 7.80 14.10 
X 7.77 8.18 10.35 9.33 11.33 
SEM 1.47 2.46 2.33 1.34 
-. 
2.66 
THE EFFECT OF FRUCTOSE, A NON-NAD + DEPENDENT PRECURSOR, 
ON GLUCOSE CONCENTRATIONS IN CONTROL (EXPERIMENTAL GROUP 1) 
AND ALCOHOL-TREATED RATS (EXPERIMENTAL GROUP 3) 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 1.50 1.90 2.90 3.10 1.50 
2. 1.30 1.70 1.70 1.90 2.00 
3. 1.20 1.10 1.60 2.30 2.00 
4. 1.30 1.10 1.80 1.80 2.00 
5. 1.20 1.70 0.9 1.80 1.80 
6. 1.20 1.50 1.60 1.90 2.50 
X 1.28 1.50 1.75 2.13 1.97 
SEM 0.04 0.13 0.26 0.20 0.13 
EXPERIMENTALS 
1. 5.10 9.50 11.30 16.20 14.00 
2. 11.40 9.90 7.70 7.10 6.20 
3. 12.80 6.40 11.60 10.50 7.20 
4. 9.50 12.90 10.50 6.50 5.50 
5. 12.90 12.60 9.60 7.40 5.40 
6. 9.80 6.50 10.80 6.60 6.30 
X 10.25 9.63 10.25 9.05 7.43 
SEM 1.18 1.15 0.58 1.55 1.32 
LACTATE CONCENTRATIONS IN CONTROL AND ALCOHOL-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 1.93 2.11 2.83 2.25 2.95 
2. 2.21 2.45 2.81 2.99 2.83 
3. 2.41 2.81 2.21 2.89 2.15 
4. 2.35 2.35 2.48 2.79 3.15 
5. 1.67 2.13 2.19 2.59 2.26 
6. 1.98 1.85 2.13 2.55 2.43 
X 2.09 2.28 2.44 2.68 2.63 
SEM 0.11 0.13 0.13 0.11 0.16 
EXPERIMENTALS 
1. 3.60 4.30 2.80 3.60 2.90 
2. 2.80 3.20 2.90 3.10 2.50 
3. 1.80 4.10 3.20 3.60 3.20 
4. 2.80 3.50 3.90 3.10 4.40 
5. 2.60 1.90 2.80 1.80 2.40 
6. 3.10 1.80 1.90 2.60 3.20 
X 2.78 3.13 2.92 2.97 3.10 
SEM 0.24 0.43 0.26 0.27 0.29 
PYRUVATE CONCENTRATIONS IN CONTROL AND ALCOHOL-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 0.156 0.221 0.218 0.221 0.195 
2. 0.222 0.204 0.201 0.181 0.203 
3. 0.214 0.208 0.151 0.195 0.159 
4. 0.158 0.219 0.222 0.161 0.185 
5. 0.241 0.195 0.218 0.144 0.201 
6. 0.151 0.201 0.206 0.221 0.201 
X 0.190 0.208 0.202 
• 
0.187 0.190 
SEM 0.010 0.040 0.010 0.010 0.008 
EXPERIMENTALS 
1. 0.103 0.130 0.101 0.107 0.120 
2. 0.115 0.100 0.130 0.100 0.109 
3. 0.105 0.120 0.104 0.100 0.106 
4. 0.115 0.115 0.102 0.120 0.200 
5. 0.102 0.107 0.110 0.106 0.101 
6. 0.108 0.104 0.120 0.113 0.130 
X 0.108 0.112 0.111 0.107 0.127 
SEM 0.004 0.004 0.004 0.'1:)04 0.010 
LACTATE:PYRUVATE RATIOS IN CONTROL AND ALCOHOL-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 12.37 9.54 12.98 10.18 15.12 
2. 9.95 12.00 13.98 16.51 13.94 
3. 11.26 13.50 14.63 14.82 13.52 
4. 14.87 10.73 11.17 17.32 17.02 
5. 6.92 10.92 10.04 17.98 11.24 
6. 13.11 9.20 10.33 11.53 12.08 
X 11.41 10.98 12.19 14.72 13.82 
SEM 1.10 0.65 0.79 1.30 0.85 
EXPERIMENTALS 
1. 34.95 33.07 27.72 33.64 24.16 
2. 24.34 32.00 22.30 31.00 22.93 
3. 17.1 4 34.16 30.76 36.00 30.18 
4. 24.34 30.43 38.23 25.83 22.00 
5. 25.49 17.75 25.45 16.98 23.76 
6. 28.70 , 17.30 15.83 23.00 24.61 
X 25.83 27.45 26.72 27.77 24.72 
SEM 2.40 3.10 3.10 2.90 1.10 
BROMOSULPHTHALEIN CLEARANCE IN CONTROL AND ALCOHOL-TREATED 
RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.849 0.588 0.598 0.193 0.085 
2. 0.884 0.629 0.638 0.151 0.086 
3. 0.842 0.582 0.514 0.172 0.093 
4. 0.852 0.608 0.618 0.181 0.062 
5. 0.846 0.603 0.522 0.196 0.082 
6. 0.848 0.621 0.584 0.186 0.091 
X 0.850 0.610 0.579 0.180 0.080 
SEM 0.008 0.008 0.010 0.008 0.004 
EXPERIMENTALS 
1. 1.266 0.619 0.621 0.633 0.667 
2. 1.135 0.466 0.503 0.410 ,0.444 
3. 0.876 0.573 0.138 0.160 0.252 
4. 0.768 0.366 0.445 0.399 0.525 
5. 1.196 0.486 0.717 0.756 0.529 
6. 0.943 0.536 0.520 0.377 0.427 
X 1.030 0.510 0.490 0.460 0.470 
SEM 0.080 0.030 0.080 0.080 0.050 
BILIARY EXCRETION OF BROMOSULPHTHALEIN IN CONTROL AND 
ALCOHOL-TREATED RATS 
CONTROL 
Time In minutes 
No. 0 5 10 15 20 
1. 0.071 0.315 0.521 0.598 0.814 
2. 0.069 0.291 0.501 0.614 0.793 
3. 0.085 0.381 0.623 0.625 0.821 
4. 0.058 0.216 0.598 0.618 0.770 
5. 0.081 0.312 0.498 0.591 0.765 
6. 0.069 0.290 0.613 0.621 0.815 
X 0.070 0.300 0.550 0.610 0.790 
SEM 0.030 0.120 0.230 0.250 0.330 
EXPERIMENTALS 
1. 0.281 0.295 0.316 0.295 0.305 
2. 0.239 0.306 0.215 0.331 0.321 
3. 0.301 0.289 0.313 0.401 0.298 
4. 0.281 0.293 0.285 0.351 0.415 
5. 0.237 0.314 0.273 0.291 0.321 
6. 0.314 0.308 0.293 0.358 0.318 
X 0.270 0.300 0.280 0.330 0.320 
SEM 0.110 0.120 0.110 0.140 0.130 
APPENDlXC 
GLUCOSE CONCENTRATIONS IN CONTROL AND RIFAMPICIN-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 2.850 2.930 3.850 3.210 3.930 
2. 3.050 3.770 4.710 4.940 5.160 
3. 2.950 3.270 3.620 17.78 18.25 
4. 2.960 2.990 3.640 3.480 7.430 
5. 2.860 3.150 3.150 3.280 3.630 
6. 2.350 2.170 3.120 2.930 3.710 
X 2.840 3.050 3.680 3.570 4.770 
SEM 0.100 0.210 0.230 0.320 0.650 
EXPERIMENTALS 
1. 1.889 2.022 1.997 1.542 2.427 
2. 1.917 1.156 1.013 2.118 1.701 
3. 1.583 1.707 1.917 2.032 1.214 
4. 1.564 1.678 1.688 1.841 1.554 
5. 13.029 2.609 2.198 2.366 1.526 
6. 1.946 1.784 2.089 1.242 2.253 
X 1.990 1.830 1.820 1.860 1.780 
SEM 0.220 0.190 0.170 0.160 0.190 
PYRUVATE CONCENTRATIONS IN CONTROL AND RIFAMPICIN-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 0.269 0.249 0.222 0.213 0.201 
2. 0.201 0.165 0.151 0.221 0.204 
3. 0.195 0.222 0.214 0.215 0.201 
4. 0.186 0.201 0.227 0.209 0.195 
5. 0.193 0.221 0.224 . 0.201 0.193 
6. 0.156 0.214 0.213 0.203 0.183 
-X 0.200 0.212 0.211 0.210 0.196 
SEM 0.010 0.010 0.010 0.004 0.004 
EXPERIMENTALS 
1. 0.106 0.130 0.105 0.104 0.155 
2. 0.120 0.105 0.101 0.159 0.161 
3. 0.111 0.122 0.110 0.102 , 0.115 
4. 0.102 0.114 0.125 0.107 0.121 
5. 0.105 0.107 0.110 0.136 0.154 
6. 0.118 0.114 0.100 0.103 0.109 
X 0.110 0.115 0.108 0.118 0.135 
SEM 0.004 0.004 0.004 0.008 0.008 
LACTATE CONCENTRATIONS IN CONTROL AND RIFAMPICIN-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 2.80 2.60 3.20 2.80 2.60 
2. 1.40 2.60 2.80 2.90 2.70 
3. 3.10 2.90 2.60 2.80 2.90 
4. 3.80 2.30 2.80 1.90 2.50 
5. 2.20 2.60 2.90 2.10 2.50 
6. 2.30 2.90 2.80 2.10 2.60 
X 2.60 2.65 2.85 2.43 2.63 
SEM 0.33 0.09 . 0.08 0.18 0.06 
EXPERIMENTALS 
1. 2.34 1.89 2.45 3.15 2.26 
2. 2.12 2.26 2.52 2.85 3.86 
3. 2.95 2.89 3.81 3.21 2.41 
4. 2.62 3.56 2.86 2.81 3.26 
5. 3.16 2.29 3.56 3.21 2.18 
6. 2.31 2.42 2.19 3.18 4.21 
X 2.58 2.55 2.73 3.07 3.03 
SEM 0.16 0.24 0.23 0.07 0.35 
LACTATE: PYRUVATE RATIOS IN CONTROL AND RIFAMPICIN-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 10.40 10.44 14.41 13.41 12.93 
2. 6.96 15.75 18.54 13.12 13.23 
3. 15.89 13.06 12.14 13.02 14.42 
4. 20.43 11.44 12.33 9.09 12.82 
5. 11.39 11.76 12.94 10.44 12.95 
6. 14.74 13.55 13.14 10.34 14.20 
X 13.30 12.67 13.92 11.53 13.43 
SEM 1.90 0.78 0.98 0.72 0.28 
EXPERIMENTALS 
1. 22.07 14.53 23.33 30.28 14.58 
2. 17.66 21.52 24.95 17.92 23.97 
3. 26.57 23.68 34.63 31.47 20.95 
4. 25.68 31.22 22.88 26.26 26.94 
5. 30.09 21.40 23.27 23.60 14.15 
6. 19.57 21.22 21.90 30.87 38.62 
X 23.61 22.26 25.16 26.73 23.20 
SEM 1.90 2.20 1.90 2.10 3.70 
BROMOSULPHTHALEIN CLEARANCE IN CONTROL AND RIFAMPICIN-TREATED 
RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.862 0.498 0.478 0.252 0.088 
2. 0.841 0.602 0.503 0.197 0.014 
3. 0.849 0.542 0.491 0.302 0.062 
4. 0.795 0.621 0.501 0.308 0.059 
5. 0.843 0.596 0.422 0.258 0.043 
6. 0.825 0.613 0.412 0.215 0.083 
X 0.840 0.580 0.467 0.250 0.050 
SEM 0.008 0.020 0.030 0.010 0.010 
EXPERIMENTALS 
1. 0.784 0.694 0.681 0.202 0.085 
2. 0.871 0.557 0.471 0.139 0.043 
3. 0.725 0.487 0.504 0.337 0.042 
4. 0.871 0.551 0.551 0.376 0.052 
5. 0.790 0.763 0.688 0.295 0.061 
6. 0.761 0.676 0.625 0.237 0.043 
X 0.800 0.620 0.580 0.260 0.050 
SEM 0.020 0.040 0.030 0.100 0.020 
APPENDIXD 
GLUCOSE CONCENTRATIONS IN CONTROL AND ISONIAZID-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 2.820 3.010 3.810 4.200 4.010 
2. 2.690 3.400 3.840 3.870 3.890 
3. 2.580 3.810 4.660 5.380 6.260 
4. 2.770 3.420 3.870 4.240 4.970 
5. 2.610 3.120 5.430 6.930 7.990 
X 2.690 3.350 4.320 4.920 5.420 
SEM 0.040 0.130 0.310 0.560 0.760 
EXPERIMENTALS 
1. 1.499 1.399 1.359 1.699 1.369 
2. 1.058 1.458 2.827 2.426 2.716 
3. 1.459 1.739 2.008 2.188 2.717 
4. 1.619 1.721 2.088 2.428 ,2.158 
5. 1.439 1.359 1.349 1.689 1.369 
X 1.410 1.540 1.930 2.090 2.070 
SEM 0.090 0.080 0.270 0.160 0.300 
LACTATE CONCENTRATIONS IN CONTROL AND ISONIAZID-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 2.14 2.25 2.38 3.49 3.51 
2. 2.16 2.88 2.56 2.38 2.65 
3. 2.23 2.56 2.95 3.21 3.41 
4. 1.85 1.98 1.99 2.15 2.75 
5. 2.31 3.13 2.18 3.45 2.65 
X 2.14 2.56 2.41 2.94 2.99 
SEM 0.07 0.20 0.16 0.28 0.19 
EXPERIMENTALS 
1. 3.81 3.15 2.26 2.45 3.41 
2. 2.86 2.47 2.52 3.81 3.16 
3. 2.26 2.58 2.89 2.39 2.62 
4. 2.57 2.63 3.17 3.21 3.15 
5. 3.14 2.95 2.49 2.95 2.73 
X 2.93 2.76 2.67 2.96 3.01 
SEM 0.26 0.12 0.16 0.26 0.14 
PYRUVATE CONCENTRATIONS IN CONTROL AND ISONIAZID-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 0.281 0.243 0.122 0.201 0.196 
2. 0.272 0.129 0.204 0.120 0.210 
3. 0.291 0.222 0.219 0.198 0.251 
4. 0.210 0.256 0.189 0.201 0.183 
5. 0.285 0.225 0.214 0.210 0.151 
X 0.267 0.215 0.189 0.186 0.198 
SEM 0.010 0.020 0.010 0.010 0.010 
EXPERIMENTALS 
1. 0.209 0.236 0.204 0.215 0.106 
2. 0.180 0.215 0.198 0.171 0.104 
3. 0.212 . 0.225 0.123 0.141 0.101 
4. 0.201 0.182 0.155 0.163 0.177 
5. 0.201 0.101 0.119 0.107 0.171 
X 0.201 0.191 0.179 0.159 0.131 
SEM 0.004 0.020 0.010 0.010 0.010 
LACTATE: PYRUVATE RATIOS IN CONTROL AND ISONIAZID-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 7.61 9.25 19.50 17.36 17.90 
2. 7.94 22.32 12.54 19.83 12.61 
3. 7.66 11 .53 13.47 16.21 13.58 
4. 8.80 7.73 10.52 10.69 15.02 
5. 8.10 13.91 10.18 16.42 17.54 
X 8.20 13.00 13.40 16.20 15.60 
SEM 0.20 2.40 1.70 1.40 1.00 
EXPERIMENTALS 
1. 18.22 13.34 11.24 11.39 32.16 
2. 15.88 11.48 12.72 22.28 30.38 
3. 10.66 11.46 23.49 16.95 25.94 
4. 12.78 14.45 20.45 19.69 ,17.79 
5. 15.62 29.02 20.92 27.57 15.96 
X 14.63 15.95 17.76 19.61 24.39 
SEM 1.30 3.30 2.40 2.70 3.20 
BROMOSULPHTHALEIN CLEARANCE IN CONTROL AND ISONIAZID-TREATED 
RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.842 0.596 0.533 0.198 0.067 
2. 0.851 0.667 0.521 0.179 0.083 
3. 0.851 0.542 0.606 0.212 0.041 
4. 0.849 0.612 0.589 0.241 0.095 
5. 0.846 0.598 0.408 0.199 0.065 
X 0.850 0.600 0.531 0.200 0.070 
SEM 0.010 0.010 0.010 0.004 0.008 
EXPERIMENTALS 
1. 0.671 0.270 0.367 0.342 0.308 
2. 0.589 0.519 0.360 0.345 0.360 
3. 0.601 0.392 0.410 0.343 0.319 
4. 0.629 0.422 0.405 0.351 0.314 
5. 0.614 0.316 0.402 0.339 0.294 
X 0.620 0.380 0.390 0.340 0.320 
SEM 0.010 0.040 0.008 0.010 0.008 
BILIARY EXCRETION OF BROMOSULPHTHALEIN IN CONTROL AND 
ISONIAZID-TREATED RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.122 0.298 0.491 0.561 0.851 
2. 0.091 0.302 0.388 0.626 0.839 
3. 0.084 0.256 0.522 0.613 0.792 
4. 0.141 0.239 0.498 0.597 0.776 
5. 0.059 0.258 0.567 0.618 0.693 
X 0.090 0.270 0.490 0.620 0.790 
SEM 0.040 0.120 0.220 0.280 . 0.350 
EXPERIMENTALS 
1. 0.287 0.339 0.389 0.318 0.406 
2. 0.113 0.317 0.321 0.298 0.392 
3. 0.198 0.295 0.289 0.315 0.388 
4. 0.217 0.319 0.301 0.328 0.379 
5. 0.188 0.401 0.256 0.403 0.368 
X 0.200 0.330 0.310 0.330 0.380 
SEM 0.090 0.150 0.140 0.150 0.170 
APPENDIX E 
GLUCOSE CONCENTRATIONS IN CONTROL AND PARACETAMOL-TREATED 
RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 2.49 2.31 3.41 2.89 3.82 
2. 2.58 2.45 3.13 4.13 3.89 
3. 1.81 2.87 2.66 5.79 4.07 
4. 1.89 2.01 2.82 3.50 3.20 
5. 1.89 2.73 3.81 4.03 4.65 
6. 1.92 2.34 2.85 3.20 3.80 
7. 2.43 2.49 1.57 3.25 4.16 
8. 2.13 2.42 1.96 2.46 1.98 
X 2.14 2.45 2.78 3.66 3.69 
SEM 0.10 0.09 0.25 0.36 0.28 
EXPERIMENTALS 
1. 0.60 1.40 0.60 1.00 1.40 
2. 1.20 0.40 1.50 0.60 1.80 
3. 1.20 1.10 1.60 1.60 3.00 
4. 0.40 0.50 1.70 1.90 2.70 
5. 0.30 1.80 1.00 1.20 1.40 
6. 1.20 0.60 0.70 1.20 2.70 
7. 1.30 1.50 1.80 0.90 1.20 
8. 1.20 0.60 0.70 1.10 1.40 
X 0.93 0.99 1.20 1.19 1.95 
SEM 0.14 0.18 0.17 0.14 0.25 
THE EFFECT OF METHYLENE BLUE, A REDOX AGENT, ON GLUCOSE CON-
CENTRATIONS IN CONTROL (EXPERIMENTAL GROUP 1) AND 
PARACETAMOL-TREATED RATS (EXPERIMENTAL GROUP 2) 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 0.60 1.40 0.60 1.00 1.40 
2. 1.20 0.40 1.50 0.60 1.80 
3. 1.20 1.10 1.60 1.60 3.00 
4. 0.40 0.50 1.70 1.90 2.70 
5. 0.30 1.80 1.00 1.20 1.40 
6. 1.20 0.60 0.70 1.20 2.70 
7. 1.30 1.50 1.80 0.90 1.20 
8. 1.20 0.60 0.70 1.10 1.40 
X 0.93 0.99 1.20 1.19 1.95 
SEM 0.14 0.18 0.17 0.14 0.25 
EXERIMENTALS 
1. 0.50 0.80 1.00 0.80 0.40 
2. 0.80 0.70 0.50 0.70 1.10 
3. 0.30 0.60 0.20 0.40 0.80 
4. 0.50 0.70 0.30 1.20 1.20 
5. 0.70 0.40 0.50 0.60 0.30 
6. 0.10 1.00 0.20 1.10 0.90 
X 0.47 0.70 0.45 0.80 0.78 
SEM 0.11 0.08 0.12 0.12 0.15 
LACTATE CONCENTRATIONS IN CONTROL AND PARACETAMOL-TREATED 
RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 1.95 1.89 2.30 2.46 3.19 
2. 1.91 2.30 2.10 2.48 2.95 
3. 1.63 2.14 2.73 2.41 3.08 
4. 2.30 2.41 2.98 2.48 2.52 
5. 1.82 2.43 2.52 2.15 3.89 
6. 1.71 2.81 2.10 2.07 3.21 
7 . . 1.68 1.94 2.15 2.15 2.83 
8. 1.72 1.92 2.14 3.14 2.85 
X 1.84 2.23 2.38 2.42 3.07 
SEM 0.07 0.22 0.11 0.12 0.14 
EXPERIMENTALS 
1. 2.50 1.80 2.10 4.00 2.30 
2. 1.30 2.10 1.90 2.80 2.90 
3. 1.70 3.20 4.00 5.40 6.90 
4. 1.80 3.20 4.40 5.00 4.50 
5. 5.40 4.10 4.90 4.40 4.70 
6. 3.80 4.90 3.90 4.20 3.40 
7. 2.50 3.80 4.50 3.00 5.10 
8. 2.70 3.00 5.60 3.80 4.90 
X 2.71 3.26 3.91 4.08 4.34 
SEM 0.47 0.36 0.46 0.31 0.51 
LACTATE: PYRUVATE RATIOS IN CONTROL AND PARACETAMOL-TREATED 
RATS 
CONTROLS 
Time In minutes 
No. 15 30 45 60 75 
1. 9.70 8.79 10.79 9.53 24.72 
2. 7.79 17.96 9.30 16.42 13.84 
3. 6.36 9.95 12.75 11.53 12.57 
4. 9.12 16.97 23.28 16.42 10.90 
5. 7.58 11.35 11.94 11.87 18.00 
6. 6.86 26.01 10.76 10.29 15.28 
7. 7.80 8.85 16.79 9.72 13.34 
8. 8.00 8.64 9.90 21.07 15.40 
X 7.90 13.57 13.19 13.36 15.51 
SEM 0.38 2.20 1.60 1.40 1.50 
EXPERIMENTALS 
1. 20.83 16.98 20.79 19.13 20.90 
2. 12.38 20.38 17.75 26.16 23.96 
3. 14.16 29.90 19.80 53.46 53.48 
4. 13.83 16.00 20.00 24.39 38.13 
5. 49.54 38.67 40.83 42.71 40.86 
6. 29.45 44.14 32.50 40.00 18.47 
7. 24.03 31.40 43.26 29.41 46.36 
8. 25.00 27.57 53.30 35.18 47.57 
X 21.01 28.12 31.03 33.81 36.22 
SEM 4.50 3.50 4.70 3.90 4.70 
PYRUVATE CONCENTRATIONS IN CONTROL AND PARACETAMOL-TREATED 
RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 0.201 0.215 0.213 0.258 0.129 
2. 0.245 0.128 0.225 0.151 0.213 
3. 0.256 0.215 0.214 0.209 0.245 
4. 0.252 0.142 0.128 0.151 0.231 
5. 0.240 0.214 0.211 0.181 0.216 
6. 0.249 0.108 0.195 0.201 0.210 
7. 0.215 0.219 0.128 0.221 0.212 
8. 0.215 0.222 0.216 0.149 0.185 
X 0.235 0.182 0.191 0.190 0.205 
SEM 0.070 0.010 0.010 0.010 0.010 
EXPERIMENTALS 
1. 0.120 0.106 0.101 0.209 0.110 
2. 0.105 0.103 0.107 0.107 0.121 
3. 0.120 0.200 0.202 0.101 0.129 
4. 0.130 0.107 0.220 0.205 0.118 
5. 0.109 \ 0.106 0.120 0.103 0.115 
6. 0.129 0.111 0.120 0.105 0.184 
7. 0.104 0.121 0.104 0.102 0.110 
8. 0.108 0.109 0.105 0.108 0.103 
X 0.115 0.120 0.134 0.129 0.123 
SEM 0.003 0.010 0.010 0.010 0.010 . 
BROMOSULPHTHALEIN CLEARANCE IN CONTROL AND PARACETAMOL-
TREATED RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.847 0.593 0.512 0.223 0.059 
2. 0.798 0.489 0.414 0.219 0.061 
3. 0.853 0.582 0.514 0.264 0.082 
4. 0.847 0.631 0.606 0.214 0.062 
5. 0.847 0.531 0.498 0.220 0.052 
6. 0.857 0.641 0.503 0.194 0.089 
7. 0.846 0.598 0.601 0.197 0.086 
8. 0.855 0.622 0.489 0.218 0.073 
X 0.840 0.590 0.517 0.220 0.070 
SEM 0.007 0.010 0.020 0.007 0.003 
EXPERIMENTALS 
1. 0.671 0.371 0.301 0.251 0.251 
2. 0.429 0.181 0.195 0.226 0.234 
3. 0.873 0.341 0.316 0.336 0.355 
4. 0.807 0.358 0.317 0.329 0.345 
5. 0.708 0.329 0.311 0.284 0.362 
6. 0.809 0.303 0.290 0.460 0.266 
X 0.720 0.310 0.290 0.310 0.300 
SEM 0.060 0.020 0.020 0.030 0.020 
BIUARY EXCRETION OF BROMOSULPHTHALEIN IN CONTROL AND 
PARACETAMOL-TREATED RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.125 0.191 0.398 0.388 0.594 
2. 0.213 0.234 0.402 0.295 0.621 
3. 0.301 0.287 0.385 . 0.423 0.588 
4. 0.156 0.299 0.374 0.517 0.713 
5. 0.082 0.310 0.421 0.601 0.820 
6. 0.063 0.285 0.285 0.481 0.798 
7. 0.114 0.277 0.391 0.492 0.,815 
8. 0.106 0.302 0.415 0.516 0.793 
X 0.140 0.?70 0.380 0.460 0.710 
SEM 0.050 0.090 0.130 0.160 0.250 
EXPERIMENTALS 
1. 0.231 0.201 0.314 0.3987 0.428 
2. 0.228 0.131 0.295 0.321 0.491 
3. 0.191 0.285 0.214 0.201 0.308 
4. 0.185 0.101 0.231 0.385 0.316 
5. 0.179 0.291 0.287 0.375 0.491 
6. 0.158 0.980 0.271 0.228 0.288 
X 0.190 0.180 0.260 0.310 0.380 
SEM 0.080 0.070 0.110 0.130 0.160 
APPENDIX F 
GLUCOSE CONCENTRATIONS IN CONTROL AND HEXANE-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 4.66 5.38 6.26 6.84 6.98 
2. 3.31 3.63 4.90 5.70 6.17 
3. 4.50 4.69 4.80 5.30 6.00 
4. 3.75 4.20 4.70 4.90 5.60 
5. 3.13 3.85 3.32 3.47 3.99 
X 3.87 4.35 4.80 5.24 5.75 
SEM 0.30 0.31 0.46 0.54 0.49 
EXPERIMENTALS 
1. 1.00 1.50 1.40 1.50 1.60 
2. 1.20 0.70 1.10 1.60 1.90 
3. 0.50 1.50 0.70 0.90 1.20 
4. 1.30 1.00 0.90 0.90 , 1.00 
5. 1.30 1.40 1.30 1.50 1.60 
X 1.06 1.22 1.08 1.28 1.46 
SEM 0.15 0.16 0.12 0.15 0.16 
THE EFFECTS OF METHYLENE BLUE, A REDOX AGENT, ON THE GLUCOSE 
CONCENTRATIONS IN CONTROL (EXPERIMENTAL GROUP 1) AND HEXANE-
TREATED RATS (EXPERIMENTAL GROUP 2) 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 1.00 1.50 1.40 1.50 1.60 
2. 1.20 0.70 1.10 1.60 1.90 
3. 0.50 1.50 0.70 0.90 1.20 
4. 1.30 1.00 0.90 0.90 1.00 
5. 1.30 1.40 1.30 1.50 1.60 
X 1.06 1.22 1.08 1.28 1.46 
SEM 0.15 0.16 0.15 0.15 0.16 
EXPERIMENTALS 
1. 1.10 1.40 1.40 1.30 1.40 
2. 1.20 0.90 1.00 1.70 1.70 
3. 1.10 1.80 0.70 0.90 1.20 
4. 1.50 1.20 0.90 1.20 1.10 
5. 1.30 1.40 1.50 1.50 1.30 
X 1.24 1.34 1.10 1.32 1.34 
SEM 0.07 0.14 0.15 0.13 0.10 
LACTATE CONCENTRATIONS IN CONTROL AND HEXANE-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 1.95 2.14 2.95 3.53 3.14 
2. 2.13 2.43 1.91 2.26 3.85 
3. 1.21 2.16 2.83 3.18 2.65 
4. 1.16 2.33 2.63 2.79 2.13 
5. 1.13 2.51 2.99 3.12 3.85 
X 1.52 2.31 2.66 2.98 3.12 
SEM 0.21 0.07 0.19 0.21 0.33 
EXPERIMENTALS 
1. 3.12 2.35 2.82 3.42 2.56 
2. 2.83 2.92 3.15 2.67 3.19 
3. 2.53 2.46 3.32 2.56 3.07 
4. 2.53 2.59 3.15 3.62 2.18 
5 2.57 2.83 3;15 3.32 3.14 
X 2.72 2.63 3.12 3.12 2.83 
SEM 0.11 0.10 0.08 0.20 0.19 
PYRUVATE CONCENTRATIONS IN CONTROL AND HEXANE-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 0.159 0.198 0.201 0.201 0.212 
2. 0.201 0.219 0.225 0.215 0.191 
3. 0.221 0.201 0.215 0.218 0.188 
4. 0.221 0.151 0.222 0.151 0.201 
5. 0.221 0.215 0.191 0.194 0.215 
X 0.204 0.196 0.210 0.195 0.201 
SEM 0.010 0.010 0.004 0.010 0.004 
EXPERIMENTALS 
1. 0.160 0.125 0.196 0.152 0.180 
2. 0.136 0.227 0.173 0.141 0.152 
3. 0.109 0.137 0.148 0.224 0.162 
4. 0.172 0.140 0.188 0.178 0.133 
5. 0.155 0.211 0.165 0.168 0.206 
X 0.146 0.168 0.155 0.172 0.166 
SEM 0.008 0.020 0.008 0.010 0.010 
LACTATE: PYRUVATE RATIOS IN CONTROL AND HEXANE-TREATED RATS 
CONTROLS 
Time in minutes 
No. 15 30 45 60 75 
1. 12.26 10.80 14.76 17.56 14.81 
2: 10.59 11.09 8.48 10.51 20.15 
3. 5.47 10.74 13.16 14.58 14.09 
4. 5.24 15.43 11.84 18.47 10.59 
5. 5.11 11.67 15.65 16.08 17.90 
X 7.73 11.95 12.78 15.44 15.51 
SEM 1.50 0.88 1.20 1.40 1.60 
EXPERIMENTALS 
1. 19.50 18.80 14.38 22.50 14.22 
2. 20.80 12.86 18.20 18.93 20.98 
3. 23.21 17.95 22.43 11.42 18.95 
4. 14.70 18.50 16.75 20.33 ,16.39 
5. 16.58 13.41 19.09 19.76 15.24 
X 18.96 16.30 18.17 18.59 17.16 
SEM 1.50 1.30 1.30 1.80 1.20 
BROMOSULPHTHALEIN CLEARANCE IN CONTROL AND HEXANE-TREATED 
RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.856 0.523 0.523 0.304 0.066 
2. 0.844 0.6222 0.601 0.285 0.086 
3. 0.841 0.610 0.521 0.212 0.090 
4. 0.849 0.621 0.693 0.218 0.098 
5. 0.852 0.682 0.524 0.245 0.096 
X 0.850 0.610 0.572 0.250 0.090 
SEM 0.004 0.020 0.004 0.010 0.004 
EXPERIMENTALS 
1. 0.656 0.253 0.332 0.295 0.287 
2. 0.573 0.315 0.326 0.303 0.292 
3. 0.633 0.270 0.291 0.2S0 0.252 
4. 0.621 0.322 0.310 0.259 0.254 
5. 0.642 0.314 0.302 0.243 0.218 
X 0.630 0.290 0.310 0.2S0 0.260 
SEM 0.010 0.010 O.OOS 0.008 0.010 
BILIARY EXCRETION OF BROMOSULPHTHALEIN IN CONTROL AND HEXANE-
TREATED RATS 
CONTROLS 
Time in minutes 
No. 0 5 10 15 20 
1. 0.131 0.298 0.391 0.523 0.701 
2. 0.091 0.325 0.388 0.618 0.823 
3. 0.180 0.316 0.439 0.493 0.719 
4. 0.203 0.293 0.516 0.591 0.693 
5. 0.078 0.285 0.435 0.602 0.813 
X 0.130 0.300 0.430 0.560 0.740 
SEM 0.060 0.130 0.190 0.250 0.340 
EXPERIMENTALS 
1. 0.281 0.315 0.381 0.392 0.406 
2. 0.313 0.287 0.325 0.356 0.392 
3. 0.215 0.303 0.369 0.392 0.408 
4. 0.320 0.351 0.358 0.408 0.352 
5. 0.251 0.362 0.319 0.356 0.428 
X 0.270 0.320 0.350 0.380 0.390 
SEM 0.120 0.140 0.150 0.170 0.180 
